<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Nature</journal-id>
        <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
        <journal-id journal-id-type="pmc-domain-id">981</journal-id>
        <journal-id journal-id-type="pmc-domain">npgopen</journal-id>
        <journal-title-group>
          <journal-title>Nature</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0028-0836</issn>
        <issn pub-type="epub">1476-4687</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>Nature Portfolio</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC3962515</article-id>
        <article-id pub-id-type="pmcid-ver">PMC3962515.2</article-id>
        <article-id pub-id-type="pmcaid">3962515</article-id>
        <article-id pub-id-type="pmcaiid">8171190</article-id>
        <article-id pub-id-type="pmid">24476821</article-id>
        <article-id pub-id-type="doi">10.1038/nature12965</article-id>
        <article-id pub-id-type="publisher-id">BFnature12965</article-id>
        <article-version article-version-type="pmc-version">2</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Comprehensive molecular characterization of urothelial bladder carcinoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <collab>The Cancer Genome Atlas Research Network<contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Weinstein</surname><given-names initials="JN">John N.</given-names></name><address><email>jweinste@mdanderson.org</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akbani</surname><given-names initials="R">Rehan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Broom</surname><given-names initials="BM">Bradley M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="W">Wenyi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Verhaak</surname><given-names initials="RGW">Roeland G. W.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McConkey</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><on-behalf-of>for the Analysis working group: The University of Texas MD Anderson Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Lerner</surname><given-names initials="S">Seth</given-names></name><address><email>slerner@bcm.edu</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morgan</surname><given-names initials="M">Margaret</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Creighton</surname><given-names initials="CJ">Chad J.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smith</surname><given-names initials="C">Carolyn</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><on-behalf-of>for the Baylor College of Medicine</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kwiatkowski</surname><given-names initials="DJ">David J.</given-names></name><address><email>dk@rics.bwh.harvard.edu</email></address><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cherniack</surname><given-names initials="AD">Andrew D.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="J">Jaegil</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sekhar Pedamallu</surname><given-names initials="C">Chandra</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Noble</surname><given-names initials="MS">Michael S.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><on-behalf-of>for the Broad Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Al-Ahmadie</surname><given-names initials="HA">Hikmat A.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reuter</surname><given-names initials="VE">Victor E.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names initials="JE">Jonathan E.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bajorin</surname><given-names initials="DF">Dean F.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bochner</surname><given-names initials="BH">Bernard H.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Solit</surname><given-names initials="DB">David B.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><on-behalf-of>for the Memorial Sloan-Kettering Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Koppie</surname><given-names initials="T">Theresa</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><on-behalf-of>for the Oregon Health and Science University, Department of Urology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Robinson</surname><given-names initials="B">Brian</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><on-behalf-of>for the Weill Medical College of Cornell University</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Gordenin</surname><given-names initials="DA">Dmitry A.</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fargo</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Klimczak</surname><given-names initials="LJ">Leszek J.</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roberts</surname><given-names initials="SA">Steven A.</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><on-behalf-of>for the National Institute of Environmental Health Sciences</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Au</surname><given-names initials="J">Jessie</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><on-behalf-of>for the Optimum Therapeutics LLC</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Laird</surname><given-names initials="PW">Peter W.</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hinoue</surname><given-names initials="T">Toshinori</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><on-behalf-of>for the University of Southern California Epigenome Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Schultz</surname><given-names initials="N">Nikolaus</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramirez</surname><given-names initials="R">Ricardo</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><on-behalf-of>for the Computational Biology Center, Memorial Sloan-Kettering Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hansel</surname><given-names initials="D">Donna</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><on-behalf-of>for the UCSD Department of Pathology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hoadley</surname><given-names initials="KA">Katherine A.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="WY">William Y.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref><xref ref-type="aff" rid="Aff22">22</xref><xref ref-type="aff" rid="Aff23">23</xref></contrib><on-behalf-of>for the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Damrauer</surname><given-names initials="JS">Jeffrey S.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref><xref ref-type="aff" rid="Aff22">22</xref></contrib><on-behalf-of>for the Department of Genetics, University of North Carolina at Chapel Hill</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Baylin</surname><given-names initials="SB">Stephen B.</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><on-behalf-of>for the The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Mungall</surname><given-names initials="AJ">Andrew J.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gordon Robertson</surname><given-names initials="A">A.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chu.</surname><given-names initials="A">Andy</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><on-behalf-of>for the Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kwiatkowski</surname><given-names initials="DJ">David J.</given-names></name><address><email>dk@rics.bwh.harvard.edu</email></address><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sougnez</surname><given-names initials="C">Carrie</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cibulskis</surname><given-names initials="K">Kristian</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lichtenstein</surname><given-names initials="L">Lee</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sivachenko</surname><given-names initials="A">Andrey</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stewart</surname><given-names initials="C">Chip</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lawrence</surname><given-names initials="MS">Michael S.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Getz</surname><given-names initials="G">Gad</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lander</surname><given-names initials="E">Eric</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gabriel.</surname><given-names initials="SB">Stacey B.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><on-behalf-of>for the Genome Sequencing Center: Broad Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Creighton</surname><given-names initials="CJ">Chad J.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Donehower</surname><given-names initials="L">Lawrence</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff26">26</xref></contrib><on-behalf-of>for the Genome characterization centres: Dan L. Duncan Cancer Center, Human Genome Sequencing Center, Baylor College of Medicine</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Cherniack</surname><given-names initials="AD">Andrew D.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="J">Jaegil</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carter</surname><given-names initials="SL">Scott L.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saksena</surname><given-names initials="G">Gordon</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schumacher</surname><given-names initials="SE">Steven E.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sougnez</surname><given-names initials="C">Carrie</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Freeman</surname><given-names initials="SS">Samuel S.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jung</surname><given-names initials="J">Joonil</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sekhar Pedamallu</surname><given-names initials="C">Chandra</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bhatt</surname><given-names initials="AS">Ami S.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pugh</surname><given-names initials="T">Trevor</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Getz</surname><given-names initials="G">Gad</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beroukhim</surname><given-names initials="R">Rameen</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gabriel</surname><given-names initials="SB">Stacey B.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meyerson</surname><given-names initials="M">Matthew</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff29">29</xref></contrib><on-behalf-of>for the Broad Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Mungall</surname><given-names initials="AJ">Andrew J.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gordon Robertson</surname><given-names initials="A">A.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chu</surname><given-names initials="A">Andy</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ally</surname><given-names initials="A">Adrian</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Balasundaram</surname><given-names initials="M">Miruna</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Butterfield</surname><given-names initials="YSN">Yaron S. N.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dhalla</surname><given-names initials="N">Noreen</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hirst</surname><given-names initials="C">Carrie</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Holt</surname><given-names initials="RA">Robert A.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="SJM">Steven J. M.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="D">Darlene</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="HI">Haiyan I.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marra</surname><given-names initials="MA">Marco A.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mayo</surname><given-names initials="M">Michael</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moore</surname><given-names initials="RA">Richard A.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schein</surname><given-names initials="JE">Jacqueline E.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sipahimalani</surname><given-names initials="P">Payal</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tam</surname><given-names initials="A">Angela</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thiessen</surname><given-names initials="N">Nina</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wong</surname><given-names initials="T">Tina</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wye</surname><given-names initials="N">Natasja</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bowlby</surname><given-names initials="R">Reanne</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chuah</surname><given-names initials="E">Eric</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guin</surname><given-names initials="R">Ranabir</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="SJM">Steven J. M.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marra</surname><given-names initials="MA">Marco A.</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><on-behalf-of>for the Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hinoue</surname><given-names initials="T">Toshinori</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="H">Hui</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bootwalla</surname><given-names initials="MS">Moiz S.</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Triche Jr</surname><given-names initials="T">Timothy</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lai</surname><given-names initials="PH">Phillip H.</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Van Den Berg</surname><given-names initials="DJ">David J.</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weisenberger</surname><given-names initials="DJ">Daniel J.</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Laird</surname><given-names initials="PW">Peter W.</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><on-behalf-of>for the University of Southern California Epigenome Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hansel</surname><given-names initials="D">Donna</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><on-behalf-of>for the UCSD Department of Pathology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hoadley</surname><given-names initials="KA">Katherine A.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Balu</surname><given-names initials="S">Saianand</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bodenheimer</surname><given-names initials="T">Tom</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Damrauer Alan P. Hoyle</surname><given-names initials="JS">Jeffrey S.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref><xref ref-type="aff" rid="Aff22">22</xref><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jefferys</surname><given-names initials="SR">Stuart R.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meng</surname><given-names initials="S">Shaowu</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mose</surname><given-names initials="LE">Lisle E.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Simons</surname><given-names initials="JV">Janae V.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soloway</surname><given-names initials="MG">Mathew G.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="J">Junyuan</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="WY">William Y.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref><xref ref-type="aff" rid="Aff22">22</xref><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parker</surname><given-names initials="JS">Joel S.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Neil Hayes</surname><given-names initials="D">D.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref><xref ref-type="aff" rid="Aff31">31</xref></contrib><on-behalf-of>for the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Roach</surname><given-names initials="J">Jeffrey</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><on-behalf-of>for the Research Computing Center, University of North Carolina at Chapel Hill</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Buda</surname><given-names initials="E">Elizabeth</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><on-behalf-of>for the Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="CD">Corbin D.</given-names></name><xref ref-type="aff" rid="Aff33">33</xref><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mieczkowski</surname><given-names initials="PA">Piotr A.</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tan</surname><given-names initials="D">Donghui</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Veluvolu</surname><given-names initials="U">Umadevi</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Waring</surname><given-names initials="S">Scot</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><on-behalf-of>for the Department of Biology, University of North Carolina at Chapel Hill</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Todd Auman</surname><given-names initials="J">J.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><on-behalf-of>for the Eshelman School of Pharmacy, University of North Carolina at Chapel Hill</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Perou</surname><given-names initials="CM">Charles M.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wilkerson</surname><given-names initials="MD">Matthew D.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><on-behalf-of>for the Department of Genetics, University of North Carolina at Chapel Hill</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Santoso</surname><given-names initials="N">Netty</given-names></name><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parfenov</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ren</surname><given-names initials="X">Xiaojia</given-names></name><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pantazi</surname><given-names initials="A">Angeliki</given-names></name><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hadjipanayis</surname><given-names initials="A">Angela</given-names></name><xref ref-type="aff" rid="Aff36">36</xref><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seidman</surname><given-names initials="J">Jonathan</given-names></name><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kucherlapati</surname><given-names initials="R">Raju</given-names></name><xref ref-type="aff" rid="Aff36">36</xref><xref ref-type="aff" rid="Aff37">37</xref></contrib><on-behalf-of>for the Department of Genetics, Harvard Medical School</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="S">Semin</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="L">Lixing</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="PJ">Peter J.</given-names></name><xref ref-type="aff" rid="Aff37">37</xref><xref ref-type="aff" rid="Aff38">38</xref><xref ref-type="aff" rid="Aff39">39</xref></contrib><on-behalf-of>for the The Center for Biomedical Informatics, Harvard Medical School</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Baylin</surname><given-names initials="SB">Stephen B.</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><on-behalf-of>for the Cancer Biology Division, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wei Xu</surname><given-names initials="A">Andrew</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><on-behalf-of>for the Division of Genetics, Brigham and Women’s Hospital</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Protopopov</surname><given-names initials="A">Alexei</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jianhua</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bristow</surname><given-names initials="C">Christopher</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mahadeshwar</surname><given-names initials="HS">Harshad S.</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seth</surname><given-names initials="S">Sahil</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Song</surname><given-names initials="X">Xingzhi</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="J">Jiabin</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zeng</surname><given-names initials="D">Dong</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chin</surname><given-names initials="L">Lynda</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff40">40</xref></contrib><on-behalf-of>for the Institute for Applied Cancer Science, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="C">Charles</given-names></name><xref ref-type="aff" rid="Aff41">41</xref><xref ref-type="aff" rid="Aff72">72</xref></contrib><on-behalf-of>for the The University of Texas MD Anderson Cancer Center, Department of Pathology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Weinstein</surname><given-names initials="JN">John N.</given-names></name><address><email>jweinste@mdanderson.org</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akbani</surname><given-names initials="R">Rehan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Broom</surname><given-names initials="BM">Bradley M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McConkey</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Casasent</surname><given-names initials="TD">Tod D.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="W">Wenbin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ju</surname><given-names initials="Z">Zhenlin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Motter</surname><given-names initials="T">Thomas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peng</surname><given-names initials="B">Bo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ryan</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="W">Wenyi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Verhaak</surname><given-names initials="RGW">Roeland G. W.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="X">Xiaoping</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="JY">Ji-Yeon</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lorenzi</surname><given-names initials="PL">Philip L.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yao</surname><given-names initials="H">Hui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="N">Nianxiang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jiexin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mills</surname><given-names initials="GB">Gordon B.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Genome data analysis centres: The University of Texas M.D. Anderson Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="J">Jaegil</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Noble</surname><given-names initials="MS">Michael S.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cho</surname><given-names initials="J">Juok</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>DiCara</surname><given-names initials="D">Daniel</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Frazer</surname><given-names initials="S">Scott</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gehlenborg</surname><given-names initials="N">Nils</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heiman</surname><given-names initials="DI">David I.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="P">Pei</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yingchun</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stojanov</surname><given-names initials="P">Petar</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Voet</surname><given-names initials="D">Doug</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="H">Hailei</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zou</surname><given-names initials="L">Lihua</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chin</surname><given-names initials="L">Lynda</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Getz</surname><given-names initials="G">Gad</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff25">25</xref></contrib><on-behalf-of>for the Broad Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Bernard</surname><given-names initials="B">Brady</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kreisberg</surname><given-names initials="D">Dick</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reynolds</surname><given-names initials="S">Sheila</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rovira</surname><given-names initials="H">Hector</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shmulevich</surname><given-names initials="I">Ilya</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><on-behalf-of>for the Institute for Systems Biology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ramirez</surname><given-names initials="R">Ricardo</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schultz</surname><given-names initials="N">Nikolaus</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="J">Jianjiong</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jacobsen</surname><given-names initials="A">Anders</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arman Aksoy</surname><given-names initials="B">B.</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Antipin</surname><given-names initials="Y">Yevgeniy</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ciriello</surname><given-names initials="G">Giovanni</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dresdner</surname><given-names initials="G">Gideon</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gross</surname><given-names initials="B">Benjamin</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="W">William</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reva</surname><given-names initials="B">Boris</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="R">Ronglai</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sinha</surname><given-names initials="R">Rileen</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Onur Sumer</surname><given-names initials="S">S.</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weinhold</surname><given-names initials="N">Nils</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ladanyi</surname><given-names initials="M">Marc</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sander</surname><given-names initials="C">Chris</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><on-behalf-of>for the Computational Biology Center, Memorial Sloan-Kettering Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Benz</surname><given-names initials="C">Christopher</given-names></name><xref ref-type="aff" rid="Aff43">43</xref><xref ref-type="aff" rid="Aff73">73</xref></contrib><on-behalf-of>for the Buck Institute for Research on Aging</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Carlin</surname><given-names initials="D">Daniel</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haussler</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ng</surname><given-names initials="S">Sam</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Paull</surname><given-names initials="EO">Evan O.</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stuart</surname><given-names initials="J">Joshua</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="J">Jing</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><on-behalf-of>for the University of California Santa Cruz</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yuexin</given-names></name><xref ref-type="aff" rid="Aff45">45</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="W">Wei</given-names></name><xref ref-type="aff" rid="Aff45">45</xref></contrib><on-behalf-of>for the Department of Pathology, MD Anderson Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Taylor</surname><given-names initials="BS">Barry S.</given-names></name><xref ref-type="aff" rid="Aff46">46</xref></contrib><on-behalf-of>for the Helen Diller Family Comprehensive Cancer Center, University of California</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Lichtenberg</surname><given-names initials="TM">Tara M.</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zmuda</surname><given-names initials="E">Erik</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barr</surname><given-names initials="T">Thomas</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Black</surname><given-names initials="AD">Aaron D.</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>George</surname><given-names initials="M">Myra</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hanf</surname><given-names initials="B">Benjamin</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Helsel</surname><given-names initials="C">Carmen</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McAllister</surname><given-names initials="C">Cynthia</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramirez</surname><given-names initials="NC">Nilsa C.</given-names></name><xref ref-type="aff" rid="Aff47">47</xref><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tabler</surname><given-names initials="TR">Teresa R.</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weaver</surname><given-names initials="S">Stephanie</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wise</surname><given-names initials="L">Lisa</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bowen</surname><given-names initials="J">Jay</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gastier-Foster</surname><given-names initials="JM">Julie M.</given-names></name><xref ref-type="aff" rid="Aff47">47</xref><xref ref-type="aff" rid="Aff48">48</xref></contrib><on-behalf-of>for the Biospecimen core resource: The Research Institute at Nationwide Children’s Hospital</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Weinstein</surname><given-names initials="JN">John N.</given-names></name><address><email>jweinste@mdanderson.org</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Tissue source sites: The University of Texas MD Anderson Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Lerner</surname><given-names initials="S">Seth</given-names></name><address><email>slerner@bcm.edu</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jian</surname><given-names initials="W">Weiguo</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tello</surname><given-names initials="S">Sebrina</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><on-behalf-of>for the Scott Department of Urology, Baylor College of Medicine</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ittman</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Castro</surname><given-names initials="P">Patricia</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McClenden</surname><given-names initials="WD">Whitney D.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morgan</surname><given-names initials="M">Margaret</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gibbs</surname><given-names initials="R">Richard</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><on-behalf-of>for the Texas Cancer Research Biobank (TCRB), Baylor College of Medicine</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yingchun</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><on-behalf-of>for the Broad Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Saller</surname><given-names initials="C">Charles</given-names></name><xref ref-type="aff" rid="Aff50">50</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tarvin</surname><given-names initials="K">Katherine</given-names></name><xref ref-type="aff" rid="Aff50">50</xref></contrib><on-behalf-of>for the Analytical Biological Services, Inc.</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>DiPiero</surname><given-names initials="JM">Jennifer M.</given-names></name><xref ref-type="aff" rid="Aff51">51</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Owens</surname><given-names initials="J">Jennifer</given-names></name><xref ref-type="aff" rid="Aff51">51</xref></contrib><on-behalf-of>for the Cleveland Clinic Foundation</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Bollag</surname><given-names initials="R">Roni</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Q">Qiang</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weinberger</surname><given-names initials="P">Paul</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><on-behalf-of>for the Georgia Regents University Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Czerwinski</surname><given-names initials="C">Christine</given-names></name><xref ref-type="aff" rid="Aff53">53</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huelsenbeck-Dill</surname><given-names initials="L">Lori</given-names></name><xref ref-type="aff" rid="Aff53">53</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Iacocca</surname><given-names initials="M">Mary</given-names></name><xref ref-type="aff" rid="Aff53">53</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Petrelli</surname><given-names initials="N">Nicholas</given-names></name><xref ref-type="aff" rid="Aff53">53</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rabeno</surname><given-names initials="B">Brenda</given-names></name><xref ref-type="aff" rid="Aff53">53</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Swanson</surname><given-names initials="P">Pat</given-names></name><xref ref-type="aff" rid="Aff53">53</xref></contrib><on-behalf-of>for the Helen F. Graham Cancer Center at Christiana Care</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Shelton</surname><given-names initials="T">Troy</given-names></name><xref ref-type="aff" rid="Aff54">54</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Curley</surname><given-names initials="E">Erin</given-names></name><xref ref-type="aff" rid="Aff54">54</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gardner</surname><given-names initials="J">Johanna</given-names></name><xref ref-type="aff" rid="Aff54">54</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mallery</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff54">54</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Penny</surname><given-names initials="R">Robert</given-names></name><xref ref-type="aff" rid="Aff54">54</xref></contrib><on-behalf-of>for the International Genomics Consortium</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Van Bang</surname><given-names initials="N">Nguyen</given-names></name><xref ref-type="aff" rid="Aff55">55</xref><xref ref-type="aff" rid="Aff56">56</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thi Hanh</surname><given-names initials="P">Phan</given-names></name><xref ref-type="aff" rid="Aff55">55</xref><xref ref-type="aff" rid="Aff56">56</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kohl</surname><given-names initials="B">Bernard</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Van Le</surname><given-names initials="X">Xuan</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Duc Phu</surname><given-names initials="B">Bui</given-names></name><xref ref-type="aff" rid="Aff55">55</xref><xref ref-type="aff" rid="Aff56">56</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thorp</surname><given-names initials="R">Richard</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Viet Tien</surname><given-names initials="N">Nguyen</given-names></name><xref ref-type="aff" rid="Aff55">55</xref><xref ref-type="aff" rid="Aff56">56</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Quang Vinh</surname><given-names initials="L">Le</given-names></name><xref ref-type="aff" rid="Aff55">55</xref><xref ref-type="aff" rid="Aff56">56</xref></contrib><on-behalf-of>for the ILSbio, LLC</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Sandusky</surname><given-names initials="G">George</given-names></name><xref ref-type="aff" rid="Aff57">57</xref></contrib><on-behalf-of>for the IU School of Medicine</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Burks</surname><given-names initials="E">Eric</given-names></name><xref ref-type="aff" rid="Aff58">58</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Christ</surname><given-names initials="K">Kimberly</given-names></name><xref ref-type="aff" rid="Aff58">58</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gee</surname><given-names initials="J">Jason</given-names></name><xref ref-type="aff" rid="Aff58">58</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Holway</surname><given-names initials="A">Antonia</given-names></name><xref ref-type="aff" rid="Aff58">58</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moinzadeh</surname><given-names initials="A">Alireza</given-names></name><xref ref-type="aff" rid="Aff58">58</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sorcini</surname><given-names initials="A">Andrea</given-names></name><xref ref-type="aff" rid="Aff58">58</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sullivan</surname><given-names initials="T">Travis</given-names></name><xref ref-type="aff" rid="Aff58">58</xref></contrib><on-behalf-of>for the Lahey Hospital and Medical Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Al-Ahmadie</surname><given-names initials="HA">Hikmat A.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bajorin</surname><given-names initials="DF">Dean F.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bochner</surname><given-names initials="BH">Bernard H.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garcia-Grossman</surname><given-names initials="IR">Ilana R.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Regazzi</surname><given-names initials="AM">Ashley M.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Solit</surname><given-names initials="DB">David B.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names initials="JE">Jonathan E.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reuter</surname><given-names initials="VE">Victor E.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><on-behalf-of>for the Memorial Sloan-Kettering Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Koppie</surname><given-names initials="T">Theresa</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><on-behalf-of>for the Oregon Health and Science University, Department of Urology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Boice</surname><given-names initials="L">Lori</given-names></name><xref ref-type="aff" rid="Aff59">59</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kimryn Rathmell</surname><given-names initials="W">Wendy</given-names></name><xref ref-type="aff" rid="Aff59">59</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thorne</surname><given-names initials="L">Leigh</given-names></name><xref ref-type="aff" rid="Aff59">59</xref></contrib><on-behalf-of>for the University of North Carolina, Lineberger Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Bastacky</surname><given-names initials="S">Sheldon</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Davies</surname><given-names initials="B">Benjamin</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dhir</surname><given-names initials="R">Rajiv</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gingrich</surname><given-names initials="J">Jeffrey</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hrebinko</surname><given-names initials="R">Ronald</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maranchie</surname><given-names initials="J">Jodi</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nelson</surname><given-names initials="J">Joel</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parwani</surname><given-names initials="A">Anil</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><on-behalf-of>for the University of Pittsburgh</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Bshara</surname><given-names initials="W">Wiam</given-names></name><xref ref-type="aff" rid="Aff61">61</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gaudioso</surname><given-names initials="C">Carmelo</given-names></name><xref ref-type="aff" rid="Aff61">61</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morrison</surname><given-names initials="C">Carl</given-names></name><xref ref-type="aff" rid="Aff61">61</xref></contrib><on-behalf-of>for the Roswell Park Cancer Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Alexopoulou</surname><given-names initials="V">Vina</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bartlett</surname><given-names initials="J">John</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Engel</surname><given-names initials="J">Jay</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kodeeswaran</surname><given-names initials="S">Sugy</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><on-behalf-of>for the Ontario Tumour Bank—Hamilton site, St Joseph’s Healthcare Hamilton</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Antic</surname><given-names initials="T">Tatjana</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>O’Donnell</surname><given-names initials="PH">Peter H.</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smith</surname><given-names initials="ND">Norm D.</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Steinberg</surname><given-names initials="GD">Gary D.</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><on-behalf-of>for the The University of Chicago</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Egea</surname><given-names initials="S">Sophie</given-names></name><xref ref-type="aff" rid="Aff64">64</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gomez-Fernandez</surname><given-names initials="C">Carmen</given-names></name><xref ref-type="aff" rid="Aff64">64</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Herbert</surname><given-names initials="L">Lynn</given-names></name><xref ref-type="aff" rid="Aff64">64</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jorda</surname><given-names initials="M">Merce</given-names></name><xref ref-type="aff" rid="Aff64">64</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soloway</surname><given-names initials="M">Mark</given-names></name><xref ref-type="aff" rid="Aff64">64</xref></contrib><on-behalf-of>for the University of Miami, Sylvester Comprehensive Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Beaver</surname><given-names initials="A">Allison</given-names></name><xref ref-type="aff" rid="Aff65">65</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carter</surname><given-names initials="S">Suzie</given-names></name><xref ref-type="aff" rid="Aff65">65</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kapur</surname><given-names initials="P">Payal</given-names></name><xref ref-type="aff" rid="Aff65">65</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lewis</surname><given-names initials="C">Cheryl</given-names></name><xref ref-type="aff" rid="Aff65">65</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lotan</surname><given-names initials="Y">Yair</given-names></name><xref ref-type="aff" rid="Aff65">65</xref></contrib><on-behalf-of>for the UT Southwestern Medical Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Robinson</surname><given-names initials="B">Brian</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><on-behalf-of>for the Weill Medical College of Cornell University</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hansel</surname><given-names initials="D">Donna</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><on-behalf-of>for the UCSD Department of Pathology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="C">Charles</given-names></name><xref ref-type="aff" rid="Aff41">41</xref><xref ref-type="aff" rid="Aff72">72</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bondaruk</surname><given-names initials="J">Jolanta</given-names></name><xref ref-type="aff" rid="Aff41">41</xref><xref ref-type="aff" rid="Aff72">72</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Czerniak</surname><given-names initials="B">Bogdan</given-names></name><xref ref-type="aff" rid="Aff41">41</xref><xref ref-type="aff" rid="Aff72">72</xref></contrib><on-behalf-of>for the The University of Texas MD Anderson Cancer Center, Department of Pathology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Akbani</surname><given-names initials="R">Rehan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Broom</surname><given-names initials="BM">Bradley M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yuexin</given-names></name><xref ref-type="aff" rid="Aff45">45</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="W">Wei</given-names></name><xref ref-type="aff" rid="Aff45">45</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Weinstein</surname><given-names initials="JN">John N.</given-names></name><address><email>jweinste@mdanderson.org</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Disease working group: The University of Texas MD Anderson Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Lerner</surname><given-names initials="S">Seth</given-names></name><address><email>slerner@bcm.edu</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><on-behalf-of>for the Scott Department of Urology, Baylor College of Medicine</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Morgan</surname><given-names initials="M">Margaret</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><on-behalf-of>for the Baylor College of Medicine</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="J">Jaegil</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cherniack</surname><given-names initials="AD">Andrew D.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Freeman</surname><given-names initials="SS">Samuel S.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sekhar Pedamallu</surname><given-names initials="C">Chandra</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Noble</surname><given-names initials="MS">Michael S.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kwiatkowski</surname><given-names initials="DJ">David J.</given-names></name><address><email>dk@rics.bwh.harvard.edu</email></address><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><on-behalf-of>for the Broad Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Al-Ahmadie</surname><given-names initials="HA">Hikmat A.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bajorin</surname><given-names initials="DF">Dean F.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bochner</surname><given-names initials="BH">Bernard H.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Solit</surname><given-names initials="DB">David B.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names initials="JE">Jonathan E.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reuter</surname><given-names initials="VE">Victor E.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><on-behalf-of>for the Memorial Sloan-Kettering Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Koppie</surname><given-names initials="T">Theresa</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><on-behalf-of>for the Oregon Health and Science University, Department of Urology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Robinson</surname><given-names initials="B">Brian</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><on-behalf-of>for the Weill Medical College of Cornell University</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Skinner</surname><given-names initials="E">Eila</given-names></name><xref ref-type="aff" rid="Aff66">66</xref></contrib><on-behalf-of>for the Stanford University, Department of Urology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ramirez</surname><given-names initials="R">Ricardo</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schultz</surname><given-names initials="N">Nikolaus</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><on-behalf-of>for the Computational Biology Center, Memorial Sloan-Kettering Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hansel</surname><given-names initials="D">Donna</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><on-behalf-of>for the UCSD Department of Pathology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="WY">William Y.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref><xref ref-type="aff" rid="Aff22">22</xref><xref ref-type="aff" rid="Aff23">23</xref></contrib><on-behalf-of>for the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="C">Charles</given-names></name><xref ref-type="aff" rid="Aff41">41</xref><xref ref-type="aff" rid="Aff72">72</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bondaruk</surname><given-names initials="J">Jolanta</given-names></name><xref ref-type="aff" rid="Aff41">41</xref><xref ref-type="aff" rid="Aff72">72</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aldape</surname><given-names initials="K">Kenneth</given-names></name><xref ref-type="aff" rid="Aff41">41</xref><xref ref-type="aff" rid="Aff72">72</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Czerniak</surname><given-names initials="B">Bogdan</given-names></name><xref ref-type="aff" rid="Aff41">41</xref><xref ref-type="aff" rid="Aff72">72</xref></contrib><on-behalf-of>for the The University of Texas MD Anderson Cancer Center, Department of Pathology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jensen</surname><given-names initials="MA">Mark A.</given-names></name><xref ref-type="aff" rid="Aff67">67</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kahn</surname><given-names initials="AB">Ari B.</given-names></name><xref ref-type="aff" rid="Aff67">67</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pihl</surname><given-names initials="TD">Todd D.</given-names></name><xref ref-type="aff" rid="Aff67">67</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pot</surname><given-names initials="DA">David A.</given-names></name><xref ref-type="aff" rid="Aff67">67</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Srinivasan</surname><given-names initials="D">Deepak</given-names></name><xref ref-type="aff" rid="Aff67">67</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wan</surname><given-names initials="Y">Yunhu</given-names></name><xref ref-type="aff" rid="Aff67">67</xref></contrib><on-behalf-of>for the Data coordination centre: SRA International</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ferguson</surname><given-names initials="ML">Martin L.</given-names></name><xref ref-type="aff" rid="Aff68">68</xref></contrib><on-behalf-of>for the Project team: MLF Consulting</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Claude Zenklusen</surname><given-names initials="J">Jean</given-names></name><xref ref-type="aff" rid="Aff69">69</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Davidsen</surname><given-names initials="T">Tanja</given-names></name><xref ref-type="aff" rid="Aff69">69</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Demchok</surname><given-names initials="JA">John A.</given-names></name><xref ref-type="aff" rid="Aff69">69</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mills Shaw</surname><given-names initials="KR">Kenna R.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff69">69</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sheth</surname><given-names initials="M">Margi</given-names></name><xref ref-type="aff" rid="Aff69">69</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tarnuzzer</surname><given-names initials="R">Roy</given-names></name><xref ref-type="aff" rid="Aff69">69</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zhining</given-names></name><xref ref-type="aff" rid="Aff69">69</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="L">Liming</given-names></name><xref ref-type="aff" rid="Aff69">69</xref></contrib><on-behalf-of>for the National Cancer Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hutter</surname><given-names initials="C">Carolyn</given-names></name><xref ref-type="aff" rid="Aff70">70</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ozenberger</surname><given-names initials="BA">Bradley A.</given-names></name><xref ref-type="aff" rid="Aff70">70</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sofia</surname><given-names initials="HJ">Heidi J.</given-names></name><xref ref-type="aff" rid="Aff70">70</xref></contrib><on-behalf-of>for the National Human Genome Research Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Eley</surname><given-names initials="G">Greg</given-names></name><xref ref-type="aff" rid="Aff71">71</xref></contrib><on-behalf-of>for the Scimentis, LLC</on-behalf-of></contrib-group></collab>
          </contrib>
          <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Bioinformatics and Computational Biology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, 77030 Texas USA </aff>
          <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Systems Biology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, 77030 Texas USA </aff>
          <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, 77030 Texas USA </aff>
          <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution>Scott Department of Urology, </institution><institution>Baylor College of Medicine, </institution></institution-wrap>Houston, 77030 Texas USA </aff>
          <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution>Texas Cancer Research Biobank (TCRB), Baylor College of Medicine, </institution></institution-wrap>Houston, 77030 Texas USA </aff>
          <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution>Human Genome Sequencing Center at Baylor College of Medicine, </institution></institution-wrap>Houston, 77030 Texas USA </aff>
          <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution>Dan L. Duncan Cancer Center, Human Genome Sequencing Center, Baylor College of Medicine, </institution></institution-wrap>Houston, 77030 Texas USA </aff>
          <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution>Baylor College of Medicine, </institution></institution-wrap>Houston, 77030 Texas USA </aff>
          <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.66859.34</institution-id><institution>The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, </institution></institution-wrap>02142 Massachusetts USA </aff>
          <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution>Brigham and Women’s Hospital, 75 Francis St, Boston, Massachusetts 02115, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Harvard Medical School, </institution></institution-wrap>Boston, 02115 Massachusetts USA </aff>
          <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.65499.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2106 9910</institution-id><institution>Department of Medical Oncology, </institution><institution>Dana-Farber Cancer Institute, </institution></institution-wrap>Boston, 02215 Massachusetts USA </aff>
          <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Memorial Sloan-Kettering Cancer Center, </institution></institution-wrap>New York, 10065 New York USA </aff>
          <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.5288.7</institution-id><institution-id institution-id-type="ISNI">0000 0000 9758 5690</institution-id><institution>Department of Urology, </institution><institution>Oregon Health and Science University, 3303 SW Bond Avenue, CHH10U, Portland, Oregon 97239, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.5386.8</institution-id><institution-id institution-id-type="ISNI">000000041936877X</institution-id><institution>Weill Medical College of Cornell University, </institution></institution-wrap>New York, 10065 New York USA </aff>
          <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.280664.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2110 5790</institution-id><institution>National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, North Carolina 27709, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.423169.b</institution-id><institution>Optimum Therapeutics LLC, 9363 Towne Centre Drive, San Diego, California 92121, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="GRID">grid.42505.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2156 6853</institution-id><institution>University of Southern California Epigenome Center, University of Southern California, </institution></institution-wrap>Los Angeles, 90033 California USA </aff>
          <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Computational Biology Center, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>UCSD Department of Pathology 9500 Gilman Drive, </institution><institution>La Jolla, California 92093, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, </institution></institution-wrap>Chapel Hill, 27599 North Carolina USA </aff>
          <aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Department of Genetics, </institution><institution>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Department of Medicine, </institution><institution>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="GRID">grid.469474.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 8617 4175</institution-id><institution>Cancer Biology Division, </institution><institution>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, </institution></institution-wrap>Baltimore, 21231 Maryland USA </aff>
          <aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="GRID">grid.32224.35</institution-id><institution-id institution-id-type="ISNI">0000 0004 0386 9924</institution-id><institution>Cancer Center and Department of Pathology, </institution><institution>Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution>Department of Molecular Virology and Microbiology, </institution><institution>Baylor College of Medicine, 1 Baylor Plaza, Houston, Texas 77030, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="GRID">grid.65499.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2106 9910</institution-id><institution>Department of Cancer Biology, </institution><institution>Dana-Farber Cancer Institute, </institution></institution-wrap>Boston, 02215 Massachusetts USA </aff>
          <aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Department of Medicine, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, 02215 Massachusetts USA </aff>
          <aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Department of Pathology, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, 02215 Massachusetts USA </aff>
          <aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="GRID">grid.248762.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 0702 3000</institution-id><institution>Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z 4S6, Canada., </institution></institution-wrap>, </aff>
          <aff id="Aff31"><label>31</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Department of Internal Medicine, Division of Medical Oncology, </institution><institution>University of North Carolina at Chapel Hill, </institution></institution-wrap>Chapel Hill, 27599 North Carolina USA </aff>
          <aff id="Aff32"><label>32</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Research Computing Center, University of North Carolina at Chapel Hill, </institution></institution-wrap>Chapel Hill, 27599 North Carolina USA </aff>
          <aff id="Aff33"><label>33</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, </institution></institution-wrap>Chapel Hill, 27599 North Carolina USA </aff>
          <aff id="Aff34"><label>34</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Department of Biology, </institution><institution>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff35"><label>35</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff36"><label>36</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Department of Genetics, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, 02115 Massachusetts USA </aff>
          <aff id="Aff37"><label>37</label><institution-wrap><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution>Division of Genetics, </institution><institution>Brigham and Women’s Hospital, </institution></institution-wrap>Boston, 02115 Massachusetts USA </aff>
          <aff id="Aff38"><label>38</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>The Center for Biomedical Informatics, Harvard Medical School, </institution></institution-wrap>Boston, 02115 Massachusetts USA </aff>
          <aff id="Aff39"><label>39</label><institution-wrap><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution>Informatics Program, Children’s Hospital, </institution></institution-wrap>Boston, 02115 Massachusetts USA </aff>
          <aff id="Aff40"><label>40</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Genomic Medicine, </institution><institution>Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, 77030 Texas USA </aff>
          <aff id="Aff41"><label>41</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Pathology, </institution><institution>The University of Texas MD Anderson Cancer Center, Unit 085; 1515 Holcombe Boulevard, </institution></institution-wrap>, </aff>
          <aff id="Aff72"><label>72</label>1515 Holcombe Boulevard, Houston, 77030 Texas USA </aff>
          <aff id="Aff42"><label>42</label><institution-wrap><institution-id institution-id-type="GRID">grid.64212.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0463 2320</institution-id><institution>Institute for Systems Biology, 401 Terry Ave N, Seattle, Washington 98109, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff43"><label>43</label><institution-wrap><institution-id institution-id-type="GRID">grid.272799.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 8687 5377</institution-id><institution>Buck Institute for Research on Aging; 8001 Redwood Blvd, Novato, California 94945, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff73"><label>73</label>8001 Redwood Blvd, Novato, California 94945, USA., , </aff>
          <aff id="Aff44"><label>44</label><institution-wrap><institution-id institution-id-type="GRID">grid.205975.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0740 6917</institution-id><institution>University California Santa Cruz, 1156 High Street, Santa Cruz, California 95064, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff45"><label>45</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Pathology, </institution><institution>MD Anderson Cancer Center, </institution></institution-wrap>Houston, 77030 Texas USA </aff>
          <aff id="Aff46"><label>46</label><institution-wrap><institution-id institution-id-type="GRID">grid.266102.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 6811</institution-id><institution>Helen Diller Family Comprehensive Cancer Center, University of California, </institution></institution-wrap>San Francisco, 94158 California USA </aff>
          <aff id="Aff47"><label>47</label><institution-wrap><institution-id institution-id-type="GRID">grid.240344.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0392 3476</institution-id><institution>The Research Institute at Nationwide Children’s Hospital, </institution></institution-wrap>Columbus, 43205 Ohio USA </aff>
          <aff id="Aff48"><label>48</label><institution-wrap><institution-id institution-id-type="GRID">grid.261331.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2285 7943</institution-id><institution>The Ohio State University, </institution></institution-wrap>Columbus, 43210 Ohio USA </aff>
          <aff id="Aff49"><label>49</label><institution-wrap><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution>Department of Pathology, </institution><institution>Baylor College of Medicine, </institution></institution-wrap>Houston, 77030 Texas USA </aff>
          <aff id="Aff50"><label>50</label><institution-wrap><institution-id institution-id-type="GRID">grid.422639.8</institution-id><institution>Analytical Biological Services, Inc., 701 Cornell Drive, Wilmington, Delaware 19801, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff51"><label>51</label><institution-wrap><institution-id institution-id-type="GRID">grid.239578.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0675 4725</institution-id><institution>Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff52"><label>52</label><institution-wrap><institution-id institution-id-type="GRID">grid.410427.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2284 9329</institution-id><institution>Georgia Regents University Cancer Center, </institution></institution-wrap>Augusta, 30912 Georgia USA </aff>
          <aff id="Aff53"><label>53</label><institution-wrap><institution-id institution-id-type="GRID">grid.414316.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 1241</institution-id><institution>Helen F. Graham Cancer Center at Christiana Care, 4701 Ogletown Stanton Road, Newark, Delaware 19713, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff54"><label>54</label><institution-wrap><institution-id institution-id-type="GRID">grid.450294.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0641 0756</institution-id><institution>International Genomics Consortium, 445 N. Fifth Street, Phoenix, Arizona 85004, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff55"><label>55</label>ILSbio, LLC 100 Radcliffe Drive, Chestertown, Maryland 21620, USA., , </aff>
          <aff id="Aff56"><label>56</label><institution-wrap><institution-id institution-id-type="GRID">grid.440261.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 4691 4473</institution-id><institution>Hue Central Hospital, </institution></institution-wrap>Hue City, Vietnam </aff>
          <aff id="Aff57"><label>57</label><institution-wrap><institution-id institution-id-type="GRID">grid.257413.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2287 3919</institution-id><institution>IU School of Medicine, Med Science Bldg, Room 128A, 635 Barnhill Drive, Indianapolis, Indiana 46202, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff58"><label>58</label><institution-wrap><institution-id institution-id-type="GRID">grid.415731.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 0725 1353</institution-id><institution>Lahey Hospital and Medical Center, Burlington, </institution></institution-wrap>01805 Massachusetts USA </aff>
          <aff id="Aff59"><label>59</label><institution-wrap><institution-id institution-id-type="GRID">grid.410711.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 1034 1720</institution-id><institution>University of North Carolina, Lineberger Cancer Center, 450 West Drive, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff60"><label>60</label><institution-wrap><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution>University of Pittsburgh, </institution></institution-wrap>Pittsburgh, 15213 Pennsylvania USA </aff>
          <aff id="Aff61"><label>61</label><institution-wrap><institution-id institution-id-type="GRID">grid.240614.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 8635</institution-id><institution>Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14063, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff62"><label>62</label><institution-wrap><institution-id institution-id-type="GRID">grid.416721.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0742 7355</institution-id><institution>Ontario Tumour Bank—Hamilton site, St Joseph’s Healthcare Hamilton, Hamilton, Ontario L8N 3Z5, Canada., </institution></institution-wrap>, </aff>
          <aff id="Aff63"><label>63</label><institution-wrap><institution-id institution-id-type="GRID">grid.170205.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7822</institution-id><institution>The University of Chicago, </institution></institution-wrap>Chicago, 60637 Illinois USA </aff>
          <aff id="Aff64"><label>64</label><institution-wrap><institution-id institution-id-type="GRID">grid.419791.3</institution-id><institution-id institution-id-type="ISNI">0000 0000 9902 6374</institution-id><institution>University of Miami, Sylvester Comprehensive Cancer Center, 1550 NW 10th Avenue, Miami, Florida 33136, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff65"><label>65</label><institution-wrap><institution-id institution-id-type="GRID">grid.267313.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 9482 7121</institution-id><institution>UT Southwestern Medical Center 5323 Harry Hines Blvd, </institution></institution-wrap>Dallas, 75390-9110 Texas USA </aff>
          <aff id="Aff66"><label>66</label><institution-wrap><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution>Department of Urology, </institution><institution>Stanford University, 300 Pasteur Drive, Suite S287, Stanford, California 94305, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff67"><label>67</label><institution-wrap><institution-id institution-id-type="GRID">grid.421489.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 4656 9526</institution-id><institution>SRA International, </institution></institution-wrap>Fairfax, 22033 Virginia USA </aff>
          <aff id="Aff68"><label>68</label>MLF Consulting, Arlington, 02474 Massachusetts USA </aff>
          <aff id="Aff69"><label>69</label><institution-wrap><institution-id institution-id-type="GRID">grid.48336.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8075</institution-id><institution>National Cancer Institute, 31 Center Drive, 3A20, Bethesda, Maryland 20892, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff70"><label>70</label><institution-wrap><institution-id institution-id-type="GRID">grid.280128.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2233 9230</institution-id><institution>National Human Genome Research Institute, 5635 Fishers Lane, Rockville, Maryland 20852, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff71"><label>71</label>Scimentis, LLC, Atlanta, Georgia 30666, USA., , </aff>
        </contrib-group>
        <pub-date pub-type="epub">
          <day>29</day>
          <month>1</month>
          <year>2014</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <year>2014</year>
        </pub-date>
        <volume>507</volume>
        <issue>7492</issue>
        <issue-id pub-id-type="pmc-issue-id">381929</issue-id>
        <fpage>315</fpage>
        <lpage>322</lpage>
        <history>
          <date date-type="received">
            <day>17</day>
            <month>6</month>
            <year>2013</year>
          </date>
          <date date-type="accepted">
            <day>19</day>
            <month>12</month>
            <year>2013</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>29</day>
              <month>01</month>
              <year>2014</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>20</day>
              <month>09</month>
              <year>2014</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2025-04-04 15:25:35.543">
              <day>04</day>
              <month>04</month>
              <year>2025</year>
            </date>
          </event>
          <event event-type="pmc-version" specific-use="live">
            <article-id pub-id-type="pmcaiid">3962515</article-id>
            <article-id pub-id-type="doi">10.1038/nature12965</article-id>
            <article-id pub-id-type="manuscript-id">NIHMS551110</article-id>
            <article-version>1</article-version>
            <pub-date>
              <day>29</day>
              <month>01</month>
              <year>2014</year>
            </pub-date>
          </event>
          <event event-type="pmc-version" specific-use="live">
            <article-id pub-id-type="pmcaiid">8171190</article-id>
            <article-id pub-id-type="doi">10.1038/nature12965</article-id>
            <article-version>2</article-version>
            <pub-date>
              <day>29</day>
              <month>01</month>
              <year>2014</year>
            </pub-date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© The Author(s) 2014</copyright-statement>
          <license>
            <ali:license_ref specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/3.0/</ali:license_ref>
            <license-p>This work is licensed under a Creative Commons Attribution-Non-Commercial-ShareAlike 3.0 Unported licence. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</ext-link>.</license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41586_2014_Article_BFnature12965.pdf"/>
        <abstract id="Abs1">
          <p>Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved for treatment of the disease. As part of The Cancer Genome Atlas project, we report here an integrated analysis of 131 urothelial carcinomas to provide a comprehensive landscape of molecular alterations. There were statistically significant recurrent mutations in 32 genes, including multiple genes involved in cell-cycle regulation, chromatin regulation, and kinase signalling pathways, as well as 9 genes not previously reported as significantly mutated in any cancer. RNA sequencing revealed four expression subtypes, two of which (papillary-like and basal/squamous-like) were also evident in microRNA sequencing and protein data. Whole-genome and RNA sequencing identified recurrent in-frame activating <italic toggle="yes">FGFR3</italic>–<italic toggle="yes">TACC3</italic> fusions and expression or integration of several viruses (including HPV16) that are associated with gene inactivation. Our analyses identified potential therapeutic targets in 69% of the tumours, including 42% with targets in the phosphatidylinositol-3-OH kinase/AKT/mTOR pathway and 45% with targets (including ERBB2) in the RTK/MAPK pathway. Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any other common cancer studied so far, indicating the future possibility of targeted therapy for chromatin abnormalities.</p>
          <sec>
            <title>Supplementary information</title>
            <p>The online version of this article (doi:10.1038/nature12965) contains supplementary material, which is available to authorized users.</p>
          </sec>
        </abstract>
        <abstract id="Abs2" abstract-type="web-summary">
          <p>This paper reports integrative molecular analyses of urothelial bladder carcinoma at the DNA, RNA, and protein levels performed as part of The Cancer Genome Atlas project; recurrent mutations were found in 32 genes, including those involved in cell-cycle regulation, chromatin regulation and kinase signalling pathways; chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any other common cancer studied so far.</p>
          <sec>
            <title>Supplementary information</title>
            <p>The online version of this article (doi:10.1038/nature12965) contains supplementary material, which is available to authorized users.</p>
          </sec>
        </abstract>
        <abstract id="Abs3" abstract-type="LongSummary">
          <title>Targeting bladder cancer</title>
          <p>This study of 131 high-grade muscle-invasive urothelial bladder carcinomas, part of The Cancer Genome Atlas (TCGA) project, reports recurrent mutations in 32 genes, including those involved in cell-cycle regulation, chromatin regulation and kinase signalling pathways. Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any common cancer studied to date. Recurrent in-frame activating <italic toggle="yes">FGFR3–TACC3</italic> fusions and expression or integration of viruses associated with gene inactivation are also identified. Importantly, potential therapeutic targets are identified in 69% of the tumours.</p>
          <sec>
            <title>Supplementary information</title>
            <p>The online version of this article (doi:10.1038/nature12965) contains supplementary material, which is available to authorized users.</p>
          </sec>
        </abstract>
        <kwd-group kwd-group-type="npg-subject">
          <title>Subject terms</title>
          <kwd>Cancer genomics</kwd>
          <kwd>Data integration</kwd>
          <kwd>Drug discovery</kwd>
          <kwd>Biomarkers</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>issue-copyright-statement</meta-name>
            <meta-value>© Springer Nature Limited 2014</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec id="Sec1">
        <title>Main</title>
        <p>Urothelial carcinoma of the bladder is a major cause of morbidity and mortality worldwide, causing an estimated 150,000 deaths per year<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Previous studies have identified multiple regions of somatic copy number alteration, including amplification of <italic toggle="yes">PPARG</italic>, <italic toggle="yes">E2F3</italic>, <italic toggle="yes">EGFR</italic>, <italic toggle="yes">CCND1</italic> and <italic toggle="yes">MDM2</italic>, as well as loss of <italic toggle="yes">CDKN2A</italic> and <italic toggle="yes">RB1</italic> (refs <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>). Sequencing of candidate pathways has identified recurrent mutations in <italic toggle="yes">TP53</italic>, <italic toggle="yes">FGFR3</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">TSC1</italic>, <italic toggle="yes">RB1</italic> and <italic toggle="yes">HRAS</italic> (refs <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>). Whole-exome sequencing of nine bladder cancers, followed by a replication analysis of 88 cancers, identified mutations at &gt;10% frequency in several chromatin remodelling genes: <italic toggle="yes">KDM6A</italic>, <italic toggle="yes">CREBBP</italic>, <italic toggle="yes">EP300</italic> and <italic toggle="yes">ARID1A</italic> (ref. <xref ref-type="bibr" rid="CR4">4</xref>). Focused molecular analyses<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup> have delineated tumour subtypes and identified kinase-activating <italic toggle="yes">FGFR3</italic> gene fusions<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>.</p>
        <p>We report here a comprehensive, integrated study of 131 high-grade muscle-invasive urothelial bladder carcinomas as part of The Cancer Genome Atlas (TCGA) project. Included are data on DNA copy number, somatic mutation, messenger RNA and microRNA (miRNA) expression, protein and phosphorylated protein expression, DNA methylation, transcript splice variation, gene fusion, viral integration, pathway perturbation, clinical correlates and histopathology to characterize the molecular landscape of urothelial carcinoma. This study identifies a number of mutations and regions of copy number variation that involve genes not previously reported as altered in a significant fraction of bladder cancers. It also identifies potential therapeutic targets in most of the samples analysed.</p>
      </sec>
      <sec id="Sec2">
        <title>Demographic, clinical and pathological data</title>
        <p>Samples (from 19 tissue source sites) consisted of 131 chemotherapy-naive, muscle-invasive, high-grade urothelial tumours (T2-T4a, Nx, Mx), as well as peripheral blood (<italic toggle="yes">n</italic> = 118) and/or tumour-adjacent, histologically normal-appearing bladder tissue (<italic toggle="yes">n</italic> = 23). Cases were retained only if they met the following criteria: tumour nuclei constituted ≥60% of all nuclei; tumour necrosis was ≤20% of the specimen; and variant histologies (squamous or small cell) were ≤50% (<xref rid="MOESM305" ref-type="media">Supplementary Information</xref>, section ‘Biospecimen collection and clinical data’). Clinical and demographic characteristics are described in <xref rid="MOESM305" ref-type="media">Supplementary Data 1.1</xref>. Five expert genitourinary pathologists re-reviewed all of the cases for multiple parameters, including the extent of variant histology (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 1.1a</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Information</xref>, section ‘Biospecimen collection and clinical data’).</p>
      </sec>
      <sec id="Sec3">
        <title>Somatic DNA alterations</title>
        <p>The tumours displayed a large number of DNA alterations, slightly fewer than in lung cancer and melanoma, but more than in other adult malignancies studied by TCGA (<xref rid="Fig1" ref-type="fig">Fig. 1</xref>)<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. On average, there were 302 exonic mutations, 204 segmental alterations in genomic copy number and 22 genomic rearrangements per sample. We analysed somatic copy number alterations (CNAs) using both SNP 6.0 arrays and low-pass whole-genome sequencing; the two were strongly concordant (<xref rid="MOESM305" ref-type="media">Supplementary Methods 6.1</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Fig. 6.1</xref>). There were 22 significant arm-level copy number changes (<xref rid="MOESM305" ref-type="media">Supplementary Data 6.1.1</xref>), and GISTIC (genomic identification of significant targets in cancer) (<xref rid="MOESM305" ref-type="media">Supplementary Methods 6.2</xref>) identified 27 amplified and 30 deleted recurrent focal somatic CNAs (<xref rid="MOESM305" ref-type="media">Supplementary Data 6.2.1 and 6.3.1</xref>). Focal amplifications involved genes previously reported to be altered in bladder cancer (<xref rid="Fig1" ref-type="fig">Fig. 1c</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Fig. 6.2.1</xref>) and some not previously implicated. The latter included <italic toggle="yes">PVRL4</italic>, <italic toggle="yes">BCL2L1</italic> and <italic toggle="yes">ZNF703</italic>. The most common recurrent focal deletion, seen in 47% of samples, contained <italic toggle="yes">CDKN2A</italic> (9p21.3) and correlated with reduced expression (<xref rid="Fig1" ref-type="fig">Fig. 1</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.7</xref>). Other focal deletions containing &lt;10 genes appeared to target <italic toggle="yes">PDE4D</italic>, <italic toggle="yes">RB1</italic>, <italic toggle="yes">FHIT</italic>, <italic toggle="yes">CREBBP</italic>, <italic toggle="yes">IKZF2</italic>, <italic toggle="yes">FOXQ1</italic>, <italic toggle="yes">FAM190A</italic> (also called <italic toggle="yes">CCSER1</italic>), <italic toggle="yes">LRP1B</italic> and <italic toggle="yes">WWOX</italic>.<fig id="Fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><title>The genomic landscape of bladder cancer.</title><p><bold>a</bold>, Mutation rate and type, histological subtype, smoking status, gender, tumour stage and cluster type. <bold>b</bold>, Genes with statistically significant levels of mutation (MutSig, false discovery rate &lt;0.1) and mutation types. <bold>c</bold>, Deletions and amplifications for genomic regions with statistically significant focal copy number changes (GISTIC2.0). ‘Copy number’ refers to absolute copy number. Note that two amplification peaks (*) contain several genes, any of which could be the target, as opposed to the single gene listed here. <bold>d</bold>, RNA expression level for selected genes, expressed as fold change from the median value for all samples. Tumour samples were grouped into three clusters (red, blue and green) using consensus NMF clustering (see the main text and <xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.1.2</xref>). Three samples with no copy number data and two samples with no mutations in the genes were not used in the clustering and are shown in grey.</p><p>
<xref rid="MOESM300" ref-type="media">PowerPoint slide</xref>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e3985" position="float" orientation="portrait" xlink:href="41586_2014_BFnature12965_Fig1_HTML.jpg"/></fig></p>
        <p>Whole-exome sequencing of 130 tumours and matched normal samples targeted 186,260 exons in 18,091 genes (mean coverage 100-fold, with 82% of target bases covered &gt;30×). MuTect<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> identified 39,312 somatic mutations (including 38,012 point mutations and 1,138 indels (insertions or deletions)), yielding mean and median somatic mutation rates of 7.7 and 5.5 per megabase (Mb), respectively (<xref rid="Fig1" ref-type="fig">Fig. 1a</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Table 2.1.1</xref>). Thirty-two genes showed statistically significant levels of recurrent somatic mutation (<xref rid="Fig1" ref-type="fig">Fig. 1b</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Table 2.1.2</xref>) by analysis using MutSig 1.5 (refs <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>) (<xref rid="MOESM305" ref-type="media">Supplementary Methods 2.2</xref>). Three other genes identified by MutSig were not considered further because of low or undetectable expression (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.1.1</xref>). A similar analysis considering only mutations in the COSMIC database<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> identified three more significantly mutated genes: <italic toggle="yes">ERBB2</italic>, <italic toggle="yes">ATM</italic> and <italic toggle="yes">CTNNB1</italic> (<xref rid="MOESM305" ref-type="media">Supplementary Table 2.1.3</xref>). We validated the mutation findings in three ways: targeted re-sequencing of all significantly mutated gene mutations, comparison with RNA-seq data for 123 samples and comparison with whole-genome sequence data for 18 samples. Overall, the validation rate was &gt;99% in selected mutations by a combination of the methods (<xref rid="MOESM305" ref-type="media">Supplementary Methods 2.4</xref>).</p>
        <p>Nearly half (49%) of the samples had <italic toggle="yes">TP53</italic> mutations (<xref rid="Fig1" ref-type="fig">Fig. 1b</xref>), which were mutually exclusive in their relationship with amplification (9%) and overexpression (29%) of <italic toggle="yes">MDM2</italic>; hence, TP53 function was inactivated in 76% of samples. Most <italic toggle="yes">RB1</italic> mutations were inactivating, were associated with significantly reduced mRNA level (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.7</xref>) and were mutually exclusive with <italic toggle="yes">CDKN2A</italic> deletions (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.8</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Table 2.8.1</xref>). <italic toggle="yes">FGFR3</italic> mutations (12%) typically affected known kinase-activating sites. <italic toggle="yes">PIK3CA</italic> mutations were relatively common (20%), clustering in the helical domain near E545 (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.4</xref>). Most <italic toggle="yes">TSC1</italic> mutations (8%) were truncating, and six were homozygous (allele fraction &gt;0.5).</p>
        <p>Many of the 32 genes identified in <xref rid="Fig1" ref-type="fig">Fig. 1b</xref> have not previously been reported as statistically significantly mutated in bladder cancer: <italic toggle="yes">MLL2</italic> (also called <italic toggle="yes">KMT2D</italic>; 27%), <italic toggle="yes">CDKN1A*</italic> (14%), <italic toggle="yes">ERCC2*</italic> (12%), <italic toggle="yes">STAG2</italic> (11%), <italic toggle="yes">RXRA*</italic> (9%), <italic toggle="yes">ELF3*</italic> (8%), <italic toggle="yes">NFE2L2</italic> (8%), <italic toggle="yes">KLF5*</italic> (8%), <italic toggle="yes">TXNIP</italic> (7%), <italic toggle="yes">FOXQ1*</italic> (5%), <italic toggle="yes">RHOB*</italic> (5%), <italic toggle="yes">FOXA1</italic> (5%), <italic toggle="yes">PAIP1*</italic> (5%), <italic toggle="yes">BTG2*</italic> (5%), <italic toggle="yes">ZFP36L1</italic> (5%), <italic toggle="yes">RHOA</italic> (4%) and <italic toggle="yes">CCND3</italic> (4%). The nine genes marked with asterisks have not been reported as significantly mutated genes in any other TCGA cancer type or reported in another study as mutated at &gt;3% frequency<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. <italic toggle="yes">CDKN1A</italic> (<italic toggle="yes">p21</italic><sup><italic toggle="yes">CIP1</italic></sup>), a cyclin-dependent kinase inhibitor<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, had predominantly null or truncating mutations, indicating loss of function. Fifteen of sixteen mutations in <italic toggle="yes">ERCC2</italic>, a nucleotide excision repair gene<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>, were deleterious missense mutations, suggesting dominant-negative effects. <italic toggle="yes">ERCC2</italic>-mutant tumours also had significantly fewer C&gt;G mutations than did <italic toggle="yes">ERCC2</italic>-wild-type tumours (<xref rid="MOESM305" ref-type="media">Supplementary Figs 2.3.1 and 2.3.2</xref>), and they trended towards higher overall mutation rate (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.12</xref>). Seven of twelve mutations in <italic toggle="yes">RXRA</italic> (retinoid X nuclear receptor alpha)<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> occurred at the same amino acid (five S427F; two S427Y) in the ligand-binding domain. Those seven tumours showed increased expression of genes involved in adipogenesis and lipid metabolism (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.6</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Data 2.6.1–2.6.3</xref>), suggesting that the mutations cause constitutive activation.</p>
        <p>Eleven tumours (8%) had deleterious missense mutations in the Neh2 domain of <italic toggle="yes">NFE2L2</italic>, a transcription factor that regulates the anti-oxidant program in response to oxidative stress<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Those tumours showed markedly increased expression of genes involved in genotoxic metabolism and the reactive oxygen species (ROS) response (<xref rid="MOESM305" ref-type="media">Supplementary Figs 2.5.1–2.5.3</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Data 2.5.2</xref>). Furthermore, nine samples had mutations in redox regulator <italic toggle="yes">TXNIP</italic> (ref. <xref ref-type="bibr" rid="CR16">16</xref>) (five of them inactivating) and were mutually exclusive of samples with <italic toggle="yes">NFE2L2</italic> mutations, providing another mechanism for dysregulation of redox metabolism. Predominant inactivating mutations were seen in STAG2, an X-linked cohesin complex component required for separation of sister chromatids during cell division<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.4</xref>).</p>
        <p>Unsupervised clustering by non-negative matrix factorization of mutations and focal somatic CNAs in 125 samples identified three distinct groups (<xref rid="Fig1" ref-type="fig">Fig. 1a</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.1.2</xref>). Group A (red), classified as ‘focally amplified’, is highly enriched in focal somatic CNAs in several genes, as well as mutations in <italic toggle="yes">MLL2</italic> (<xref rid="Fig1" ref-type="fig">Fig. 1</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Tables 2.1.4 and 2.1.5</xref>). Group B (blue), classified as ‘papillary <italic toggle="yes">CDKN2A</italic>-deficient <italic toggle="yes">FGFR3</italic> mutant’, is enriched in papillary histology. Nearly all group B samples show loss of <italic toggle="yes">CDKN2A</italic>, and most have one or more alterations in <italic toggle="yes">FGFR3</italic>. Group C (green), classified as ‘<italic toggle="yes">TP53</italic>/cell-cycle-mutant’, shows <italic toggle="yes">TP53</italic> mutations in nearly all samples, as well as enrichment with <italic toggle="yes">RB1</italic> mutations and amplifications of <italic toggle="yes">E2F3</italic> and <italic toggle="yes">CCNE1</italic> (<xref rid="Fig1" ref-type="fig">Fig. 1</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Table 2.1.4</xref>). These differences in pattern of mutation suggest the possibility of different oncogenic mechanisms.</p>
        <p>Seventy-two per cent of the cancers in this study were from current or past smokers, consistent with extensive epidemiological studies indicating an association between smoking and urothelial cancer risk. In contrast with lung cancer, however, there was no statistically significant association between smoking status and the mutational spectrum, frequency of mutation in any significantly mutated gene, occurrence of focal somatic CNAs or expression subtype (<xref rid="MOESM305" ref-type="media">Supplementary Tables 2.9.1 and 2.9.2</xref>). Never-smokers did have a slightly higher fraction of C&gt;G mutations than did current/former smokers (28.5% versus 23.8%, <italic toggle="yes">P</italic> = 0.032; <xref rid="MOESM305" ref-type="media">Supplementary Figs 2.3.2 and 2.3.3</xref>). Unsupervised clustering of promoter CpG island DNA methylation data revealed a major subgroup (34%) of tumours (CIMP) characterized by cancer-specific DNA hypermethylation (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 7.1</xref>). Multivariate regression analysis with age, sex and tumour stage as covariates identified smoking pack-years as the only significant predictor of CIMP phenotype, as has also been reported for colorectal cancer<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>.</p>
        <p>Fifty-one per cent of mutations overall were Tp*C-&gt;(T/G) (<xref rid="MOESM305" ref-type="media">Supplementary Table 2.1.1</xref>), a class of mutation recently reported to be mediated by one of the DNA cytosine deaminases, APOBEC (refs <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>). <italic toggle="yes">APOBEC3B</italic> was expressed at high levels in all of the tumours, suggesting a major role for APOBEC-mediated mutagenesis in bladder carcinogenesis (<xref rid="MOESM305" ref-type="media">Supplementary Figs 12.1 and 12.2</xref>).</p>
        <p>Four genes involved in epigenetic regulation were significantly mutated genes: <italic toggle="yes">MLL2</italic>, <italic toggle="yes">ARID1A</italic>, <italic toggle="yes">KDM6A</italic> and <italic toggle="yes">EP300</italic> (<xref rid="Fig1" ref-type="fig">Fig. 1</xref>). Truncating mutations were significantly enriched in each of those genes (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.2</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Data 2.2.1–2</xref>). Three of the genes had previously been identified as mutated in urothelial cancers<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, but mutation of <italic toggle="yes">MLL2</italic>, which encodes a histone H3 lysine 4 (H3K4) methyltransferase, is a novel finding. Several other chromatin-regulating genes had mutation rates ≥10% but were not statistically significant by MutSig analysis: <italic toggle="yes">MLL3</italic>, <italic toggle="yes">MLL</italic>, <italic toggle="yes">CREBBP</italic>, <italic toggle="yes">CHD7</italic> and <italic toggle="yes">SRCAP.</italic> Many other epigenetic regulators were mutated at lower frequency but were also enriched with truncating mutations, indicating functional significance (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.2</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Data 2.2.1 and 2.2.2</xref>). Non-silent mutations in chromatin regulatory genes overall were significantly enriched in bladder cancer in comparison with the entire exome, in contrast with all other epithelial cancers studied so far in the TCGA project (<xref rid="MOESM305" ref-type="media">Supplementary Table 2.10</xref>). Mutations in <italic toggle="yes">MLL2</italic> and <italic toggle="yes">KDM6A</italic> (the latter encoding a histone H3 lysine 27 (H3K27) demethylase) were mutually exclusive (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 2.8</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Table 2.8.1</xref>), suggesting that mutations in the two genes have redundant downstream effects on carcinogenesis or that the combined loss is synthetically lethal.</p>
      </sec>
      <sec id="Sec4">
        <title>Chromosomal rearrangements and viral integration</title>
        <p>To identify structural variations and pathogen sequences, we used low-pass, paired-end, whole-genome sequencing (WGS; 6–8× coverage) of 114 tumours and RNA sequencing of all tumours. We detected 2,529 structural aberrations, including 1,153 that involve gene–gene fusions. Among the translocations, 379 were inter-chromosomal, 237 were intra-chromosomal, 274 were the result of inversions and 263 resulted from deletions (<xref rid="MOESM305" ref-type="media">Supplementary Table 3.1</xref>). We found several recurrent translocations of probable pathogenic significance, including an intra-chromosomal translocation on chromosome 4 involving <italic toggle="yes">FGFR3</italic> and <italic toggle="yes">TACC3</italic> (<italic toggle="yes">n</italic> = 3). The breakpoints were in intron 16 (two cases) or exon 17 (one case) of <italic toggle="yes">FGFR3</italic> and intron 10 of <italic toggle="yes">TACC3</italic> (confirmed by DNA sequencing and RNA-seq). All three lead to fusion mRNA products for which the predicted proteins include the amino-terminal 758 amino acids of FGFR3 fused with the carboxy-terminal 191 amino acids of TACC3 (<xref rid="Fig2" ref-type="fig">Fig. 2a</xref>). On the basis of the structure of the FGFR3–TACC3 fusion protein, we predict that it can auto-dimerize, leading to constitutive activation of the kinase domain of FGFR3. FGFR3–TACC3 fusion, which was recently described in both glioblastoma<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> and bladder cancer<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>, represents a promising therapeutic target. The <italic toggle="yes">ERBB2</italic> gene was also involved in translocations in four tumours, all with different fusion partners and all confirmed by DNA sequencing, RNA-seq or both. In one case, exons 4 to 29 of <italic toggle="yes">ERBB2</italic> were fused to the promoter plus exon 1 of <italic toggle="yes">DIP2B</italic>, and the fusion product was amplified (<xref rid="Fig2" ref-type="fig">Fig. 2b</xref>). Two other fusion products resulted in novel mRNA products, the biological significance of which is not known.<fig id="Fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><title>Structural rearrangements and viral integration.</title><p><bold>a</bold>, FGFR3–TACC3 fusion in sample TCGA-CF-A3MH showing the breakpoints in the two genes, the breakpoint junction sequences and the predicted fusion protein. <bold>b</bold>, Rearrangement involving <italic toggle="yes">DIP2B</italic> and <italic toggle="yes">ERBB2</italic> in TCGA-DK-A2I6. The <italic toggle="yes">ERBB2</italic> gene has swapped its promoter with that of <italic toggle="yes">DIP2B</italic>, resulting in overexpression of <italic toggle="yes">ERBB2</italic>. <bold>c</bold>, Insertion of human papilloma virus 16 (HPV16) into the <italic toggle="yes">BCL2L1</italic> gene on chromosome 20 in TCGA-GC-A3I6. The region of <italic toggle="yes">BCL2L1</italic> into which the virus has integrated and the integration junction sequence are shown.</p><p>
<xref rid="MOESM301" ref-type="media">PowerPoint slide</xref>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e4474" position="float" orientation="portrait" xlink:href="41586_2014_BFnature12965_Fig2_HTML.jpg"/></fig></p>
        <p>We identified viral DNAs in 7 of 122 tumours (6%), and viral transcripts in 5 of 122 (4%). Three tumours expressed cytomegalovirus (CMV) transcripts (encoding RL5A, RNA2.7, RL9A, RNA1.2, UL5 and UL22A), one expressed BK polyoma virus and one expressed human papilloma virus 16 (HPV16). HPV16 and human herpesvirus 6B DNA were each identified in one other sample but without expression. None of the tumours expressing CMV showed evidence of CMV integration into the host genome, suggesting the presence of a stable episome. In the BK-positive tumour, two BK genes were integrated into <italic toggle="yes">GRB14</italic>, a signalling adaptor protein for receptor tyrosine kinases. In the HPV-16-expressing case, the virus integrated into <italic toggle="yes">BCL2L1</italic>, an apoptosis-regulating gene (<xref rid="Fig2" ref-type="fig">Fig. 2c</xref>). In that tumour, <italic toggle="yes">BCL2L1</italic> was amplified (∼6×) and overexpressed (∼10× median; &gt;2× any of the other samples). Overall, these findings indicate that viral infection may have a role in the development of a small percentage of urothelial carcinomas.</p>
      </sec>
      <sec id="Sec5">
        <title>mRNA, miRNA and protein expression</title>
        <p>Analysis of RNA-seq data from 129 tumours identified four clusters (clusters I–IV) (<xref rid="Fig3" ref-type="fig">Fig. 3</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Fig. 4.1</xref>). Cluster I (‘papillary-like’) is enriched in tumours with papillary morphology (<italic toggle="yes">P</italic> = 0.0002), <italic toggle="yes">FGFR3</italic> mutations (<italic toggle="yes">P</italic> = 0.0007, <italic toggle="yes">q</italic> = 0.02), <italic toggle="yes">FGFR3</italic> copy number gain (<italic toggle="yes">P</italic> = 0.04, <italic toggle="yes">q</italic> = 0.1) and elevated FGFR3 expression (<italic toggle="yes">P</italic> &lt; 0.0001) (<xref rid="Fig3" ref-type="fig">Fig. 3a</xref>). It includes all three samples with <italic toggle="yes">FGFR3–TACC3</italic> fusions. Cluster I samples also show significantly lower expression of miR-99a and miR-100, miRNAs that downregulate <italic toggle="yes">FGFR3</italic> expression (<italic toggle="yes">P</italic> = 0.0002, <xref rid="Fig3" ref-type="fig">Figs 3a</xref> and <xref rid="MOESM305" ref-type="media">Supplementary Fig. 5.3</xref>)<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Cluster I samples also show lower expression of miR-145 and miR-125b, which have been reported as frequently downregulated in bladder cancer<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Tumours with <italic toggle="yes">FGFR3</italic> alterations, and perhaps other tumours that share the cluster I expression profile, may respond to inhibitors of FGFR or its downstream targets.<fig id="Fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><title>Expression characteristics of bladder cancer.</title><p>Integrated analysis of mRNA, miRNA and protein data led to identification of distinct subsets of urothelial carcinoma. Data for mRNA, miRNA and protein were <italic toggle="yes">z</italic>-normalized, and samples were organized in the horizontal direction by mRNA clustering. <bold>a</bold>, Papillary histology, <italic toggle="yes">FGFR3</italic> alterations, <italic toggle="yes">FGFR3</italic> expression and reduced <italic toggle="yes">FGFR3</italic>-related miRNA expression are enriched in cluster I. <bold>b</bold>, Expression of epithelial lineage genes and stem/progenitor cytokeratins are generally high in cluster III, some of which show variant squamous histology. <bold>c</bold>, Luminal breast and urothelial differentiation factors are enriched in clusters I and II. <bold>d</bold>, <italic toggle="yes">ERBB2</italic> mutation and oestrogen receptor beta (<italic toggle="yes">ESR2</italic>) expression are enriched in clusters I and II.</p><p>
<xref rid="MOESM302" ref-type="media">PowerPoint slide</xref>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e4602" position="float" orientation="portrait" xlink:href="41586_2014_BFnature12965_Fig3_HTML.jpg"/></fig></p>
        <p>Reverse-phase protein array (RPPA) data indicate that clusters I and II express high HER2 (ERBB2) levels and an elevated oestrogen receptor beta (ESR2) signalling signature, indicating potential targets for hormone therapies such as tamoxifen or raloxifene (<xref rid="Fig3" ref-type="fig">Fig. 3d</xref>). In fact, HER2 protein levels in a subset of the tumours are comparable to those found in TCGA HER2-positive breast cancers<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>.</p>
        <p>For comparison, we asked whether any of the four clusters show gene signatures similar to those identified in any other tumour type(s) among the first 11 analysed by TCGA. We found that the signature of bladder cancer cluster III (‘basal/squamous-like’) is similar to that of basal-like breast cancers, as well as squamous cell cancers of the head and neck and lung (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 4.2</xref>)<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. All four of those cancer types express characteristic epithelial lineage genes, including <italic toggle="yes">KRT14</italic>, <italic toggle="yes">KRT5</italic>, <italic toggle="yes">KRT6A</italic> and <italic toggle="yes">EGFR</italic>. Basal-like subtype<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> and squamous cell subtype<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> of urothelial carcinoma have been independently reported. Many of the samples in bladder cluster III express cytokeratins (that is, <italic toggle="yes">KRT14</italic> and <italic toggle="yes">KRT5</italic>) that were recently reported to mark stem/progenitor cells<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Some of those samples also show a level of variant squamous histology (<xref rid="Fig3" ref-type="fig">Fig. 3b</xref>). Bladder clusters I and II show features similar to those of luminal A breast cancer, with high mRNA and protein expression of luminal breast differentiation markers, including GATA3 and FOXA1 (<xref rid="Fig3" ref-type="fig">Fig. 3c</xref>). Markers of urothelial differentiation such as the uroplakins (for example, UPK3A) are also highly expressed in clusters I and II, as are the epithelial marker E-cadherin and members of the miR-200 family of miRNAs (which target multiple regulators of epithelial–mesenchymal transition)<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> (<xref rid="Fig3" ref-type="fig">Fig. 3c</xref>). Taken together, these observations indicate that, despite their diverse tissue origins, some bladder, breast, head and neck and lung cancers share common pathways of tumour development.</p>
        <p>To determine whether the expression-based clusters could be seen in other data sets, we used the muscle-invasive bladder cancer samples from ref. <xref ref-type="bibr" rid="CR27">27</xref>, hierarchically clustering them with the genes used in our analysis. From the sample dendrogram, we identified four groups (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 4.3a</xref>). The four groups identified in the data set of ref. <xref ref-type="bibr" rid="CR27">27</xref> correlated well with the four clusters identified in our TCGA data (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 4.3b</xref>).</p>
        <p>When we analysed the RNA-seq data for transcript splice variation using SpliceSeq<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> (<xref rid="MOESM305" ref-type="media">Supplementary Information</xref>, section 11), one finding of interest was an average of 3% <italic toggle="yes">PKM1</italic> and 97% <italic toggle="yes">PKM2</italic> transcripts in the tumour samples. The <italic toggle="yes">PKM2</italic> isoform of pyruvate kinase is the principal driver of a shift to aerobic glycolysis in tumours (the Warburg effect)<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Therefore, urothelial bladder cancers (and other cancer types) may prove sensitive to inhibition of glycolysis or related metabolic pathways.</p>
      </sec>
      <sec id="Sec6">
        <title>Pathway analysis and therapeutic targeting</title>
        <p>Integrated analysis of the mutation and copy-number data revealed three main pathways as frequently dysregulated in bladder cancer: cell cycle regulation (altered in 93% of cases); kinase and phosphatidylinositol-3-OH kinase (PI(3)K) signalling (72%); and chromatin remodelling, including mutations/somatic CNAs in histone-modifying genes (89%) and components of the SWI/SNF nucleosome remodelling complex (64%) (<xref rid="Fig4" ref-type="fig">Fig. 4a</xref>). To complement these results for well-defined pathways, we applied network analysis methods to examine other possible interactions between genes and pathways (<xref rid="Fig4" ref-type="fig">Fig. 4b</xref>). In particular, we used the TieDIE algorithm to search for causal regulatory interactions within the PARADIGM network, which connects mutated genes to active transcriptional hubs<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. The analysis identified a sub-network linking mutated histone-modifying genes to a large array of activated transcription factors, indicating potential far-reaching effects of histone modification on other pathways (<xref rid="MOESM305" ref-type="media">Supplementary Fig. 8.2.1</xref>) converging on MYC/MAX regulation. Both MYC and MAX showed similar levels of pathway activity, independent of mutations in chromatin genes, suggesting that mutations in histone-modifying genes provide just one mechanism for disruption of the MYC/MAX hub. By contrast, tumours with chromatin-related mutations showed differential activity of transcription factors <italic toggle="yes">FOXA2</italic> and <italic toggle="yes">SP1</italic>, implicating de-differentiation processes as a result of the mutations. Our network analysis also identified <italic toggle="yes">HSP90AA1</italic> as a critical signalling hub, indicating that inhibitors of HSP90 may have therapeutic value in urothelial carcinoma. Although the linkages between mutations and transcriptional changes were statistically significant in terms of their proximity in the network (as determined by permutation tests; see <xref rid="MOESM305" ref-type="media">Supplementary Fig. 8.2</xref>), further studies will be needed to assess the biological relevance of the findings.<fig id="Fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><title>Altered pathways and networks in bladder cancer.</title><p><bold>a</bold>, Somatic mutations and copy number alterations (CNA) in components of the p53/Rb pathway, RTK/RAS/PI(3)K pathway, histone modification system and SWI/SNF complex. Red, activating genetic alterations; blue, inactivating genetic alterations. Percentages shown denote activation or inactivation of at least one allele. <bold>b</bold>, The network connecting mutated histone-modifying genes to transcription factors with differential activity (methodology and larger implicated network in <xref rid="MOESM305" ref-type="media">Supplementary Fig. 8.2.1</xref>). Each gene is depicted as a multi-ring circle with various levels of data, plotted such that each ‘spoke’ in the ring represents a single patient sample (same sample ordering for all genes). ‘PARADIGM’ ring, bioinformatically inferred levels of gene activity (red, higher activity); ‘Transcriptional activity’, mean mRNA levels of all of the targets of each transcription factor; ‘expression’, mRNA levels relative to normal (red, high); ‘Mutation in gene’, somatic mutation; ‘Mutation in histone modifier genes’, somatic mutation in at least one such gene; ‘IPL anti-correlation’, genes with PARADIGM integrated pathway levels (IPLs) inversely correlated with histone-gene mutation status. Gene–gene relationships are inferred using public resources.</p><p>
<xref rid="MOESM303" ref-type="media">PowerPoint slide</xref>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e4763" position="float" orientation="portrait" xlink:href="41586_2014_BFnature12965_Fig4_HTML.jpg"/></fig></p>
        <p>Integrated analysis also identified mutations, copy number alterations or RNA expression changes affecting the PI(3)K/AKT/mTOR pathway in 42% of the tumours (<xref rid="Fig5" ref-type="fig">Fig. 5a</xref>). Included were activating point mutations in <italic toggle="yes">PIK3CA</italic> (17%; potentially responsive to PI(3)K inhibitors), mutation or deletion of <italic toggle="yes">TSC1</italic> or <italic toggle="yes">TSC2</italic> (9%; potentially responsive to mTOR inhibitors) and overexpression of <italic toggle="yes">AKT3</italic> (10%; potentially responsive to AKT inhibitors). We also observed mutations, genomic amplifications or gene fusions that affect the RTK/RAS pathway in 44% of the tumours (<xref rid="Fig5" ref-type="fig">Fig. 5b, c</xref>). Included were events that can activate FGFR3 (17%; potentially responsive to FGFR inhibitors or antibodies), amplification of EGFR (9%; potentially responsive to EGFR antibodies or inhibitors), mutations of <italic toggle="yes">ERBB3</italic> (6%; potentially sensitive to ERBB kinase inhibitors) and mutation or amplification of <italic toggle="yes">ERBB2</italic> (9%; potentially sensitive to ERBB2 kinase inhibitors or antibodies). <italic toggle="yes">ERBB3</italic> mutations in bladder cancer have been noted previously<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, but statistically significant mutation of <italic toggle="yes">ERBB2</italic> in bladder cancer has not been reported. Both genes are potential therapeutic targets in other diseases<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. Notably, <italic toggle="yes">ERBB2</italic> alterations were approximately as frequent in this study as in TCGA breast cancers, but with fewer amplifications and more mutations (<xref rid="Fig5" ref-type="fig">Fig. 5d</xref>)<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>.<fig id="Fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><title>Potential targets in bladder cancer.</title><p><bold>a</bold>, Alterations in the PI(3)K/AKT/mTOR pathway are mutually exclusive. Tumour samples are shown in columns; genes in rows. Only samples with at least one alteration are shown. AKT3 shows elevated expression in 10% of samples, independent of copy number (right panel). Hetloss, heterozygous loss. <bold>b</bold>, Receptor tyrosine kinases are altered, by any of several different mechanisms (amplification, mutation or fusion), in 45% of samples. Only mutations that are recurrent in this data set or previously reported in COSMIC are shown. <bold>c</bold>, Recurrent mutations in ERBB2 and ERBB3. The mutations shown in black are either recurrent in the TCGA data set or reported in COSMIC. Green, receptor L domain; red, furin-like cysteine-rich region; blue, growth factor receptor domain IV; yellow, tyrosine kinase domain. <bold>d</bold>, <italic toggle="yes">ERBB2</italic> amplifications and recurrent mutations in other cancers profiled by TCGA. Missense mutations were counted in the following positions: G309, S310, L313, R678, T733, L755, V777, D769, V842, T862, R896 and M916I. In-frame insertions were counted between amino acids 774 and 776. Only tumour types with an alteration frequency ≥2% are shown.</p><p>
<xref rid="MOESM304" ref-type="media">PowerPoint slide</xref>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e4851" position="float" orientation="portrait" xlink:href="41586_2014_BFnature12965_Fig5_HTML.jpg"/></fig></p>
      </sec>
      <sec id="Sec7">
        <title>Discussion</title>
        <p>This integrated study of 131 invasive urothelial bladder carcinomas provides numerous novel insights into disease biology and delineates multiple potential opportunities for therapeutic intervention. Treatment for muscle-invasive bladder cancer has not advanced beyond cisplatin-based combination chemotherapy and surgery in the past 30 years<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, and no new drugs for the disease have been approved in that time. Median survival for patients with recurrent or metastatic bladder cancer remains 14–15 months with cisplatin-based chemotherapy, and there is no widely recognized second-line therapy<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. With the exception of a single case report, there is also no known benefit from treatment with newer, targeted agents<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. Several of the genomic alterations identified in this study, particularly those involving the PI(3)K/AKT/mTOR, CDKN2A/CDK4/CCND1 and RTK/RAS pathways, including ERBB2 (Her-2), ERBB3 and FGFR3, are amenable in principle to therapeutic targeting. Clinical trials based on patients with relevant druggable genomic alterations are warranted.</p>
        <p><italic toggle="yes">FGFR3</italic> mutation is a common feature of low-grade non-invasive papillary urothelial bladder cancer, but it occurs at a much lower frequency in high-grade invasive bladder cancer. The cluster analysis in <xref rid="Fig3" ref-type="fig">Fig. 3</xref> highlights multiple mechanisms of <italic toggle="yes">FGFR3</italic> activation, and its strong association with papillary morphology. The data presented here suggest a subset of muscle-invasive cancers that can potentially be targeted through <italic toggle="yes">FGFR3</italic>. Similarly, ERBB2 amplification may be targetable by strategies used in breast cancer, by small-molecule tyrosine kinase inhibitors or by novel immunotherapeutic approaches (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01353222">NCT01353222</ext-link>)<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. The data here provide further support for several on-going ERBB2-targeted trials in bladder cancer and further define the subpopulation of cancers suited to that approach. Finally, cluster III of the integrated expression profiling analysis reveals the existence of a urothelial carcinoma subtype with cancer stem-cell expression features (including KRT14 and KRT5), perhaps providing another avenue for therapeutic targeting.</p>
        <p>The alterations identified in epigenetic pathways also suggest new possibilities for bladder cancer treatment. Ninety-nine (76%) of the tumours analysed here had an inactivating mutation in one or more of the chromatin regulatory genes, and 53 (41%) had at least two such mutations. Overall, the bladder cancers showed a mutational spectrum highly enriched with mutations in chromatin regulatory genes (<xref rid="MOESM305" ref-type="media">Supplementary Table 2.10</xref>). Furthermore, integrated network analyses revealed a profound impact of those mutations on the activity levels of various transcription factors and pathways implicated in cancer. Drugs that target chromatin modifications—for example, recently developed agents that bind acetyl-lysine binding motifs (bromodomains)—might prove useful for treatment of the subset of bladder tumours that exhibit abnormalities in chromatin-modifying enzymes<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Our findings overall indicate bladder cancer as a prime candidate for exploration of that approach to therapy.</p>
      </sec>
      <sec id="Sec8">
        <title>Methods Summary</title>
        <p>Tumour and normal samples were obtained with institutional-review-board-approved consent and processed using a modified AllPrep kit (Qiagen) to obtain purified DNA and RNA. Quality-control analyses revealed only modest batch effects (<xref rid="MOESM305" ref-type="media">Supplementary Information</xref>, section ‘Batch effects’). The tumours were profiled using Affymetrix SNP 6.0 microarrays for somatic CNAs, low-pass WGS (HiSeq) for somatic CNAs and translocations, RNA-seq (HiSeq) for mRNA and miRNA expression, Illumina Infinium (HumanMethylation450) arrays for DNA methylation, HiSeq for exome sequencing and RPPA for protein expression and phosphorylation. Statistical analysis and biological interpretation of the data were spearheaded by the TCGA genome data analysis centres. Sequence files are in CGHub (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cghub.ucsc.edu/">https://cghub.ucsc.edu/</ext-link>). All other molecular, clinical and pathological data are available through the TCGA Data Portal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/">https://tcga-data.nci.nih.gov/tcga/</ext-link>). The data can be explored through a compendium of next-generation clustered heat maps (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinformatics.mdanderson.org/TCGA/NGCHMPortal/">http://bioinformatics.mdanderson.org/TCGA/NGCHMPortal/</ext-link>), the cBio Cancer Genomics Portal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cbioportal.org">http://cbioportal.org</ext-link>), TieDIE (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://sysbiowiki.soe.ucsc.edu/tiedie">http://sysbiowiki.soe.ucsc.edu/tiedie</ext-link>), SpliceSeq (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinformatics.mdanderson.org/main/SpliceSeq:Overview">http://bioinformatics.mdanderson.org/main/SpliceSeq:Overview</ext-link>), MBatch batch effects assessor (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinformatics.mdanderson.org/tcgambatch/">http://bioinformatics.mdanderson.org/tcgambatch/</ext-link>) and Regulome Explorer (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://explorer.cancerregulome.org/">http://explorer.cancerregulome.org/</ext-link>). Also see <xref rid="MOESM305" ref-type="media">Supplementary Information</xref>.</p>
      </sec>
      <sec sec-type="supplementary-material">
        <title>Supplementary information</title>
        <sec id="Sec9">
          <p>
<supplementary-material content-type="local-data" id="MOESM305" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41586_2014_BFnature12965_MOESM305_ESM.pdf" position="float" orientation="portrait"><caption><title>Supplementary Information</title><p>This file contains Supplementary Text and Data, Supplementary Figures, Supplementary Tables and additional references – see Contents for details. (PDF 18005 kb)</p></caption></media></supplementary-material>
</p>
        </sec>
      </sec>
    </body>
    <back>
      <app-group>
        <app id="App1">
          <sec id="Sec10">
            <title>PowerPoint slides</title>
            <p>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="41586_2014_BFnature12965_MOESM300_ESM.ppt" id="MOESM300" orientation="portrait"><caption><p>PowerPoint slide for Fig. 1</p></caption></media>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="41586_2014_BFnature12965_MOESM301_ESM.ppt" id="MOESM301" orientation="portrait"><caption><p>PowerPoint slide for Fig. 2</p></caption></media>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="41586_2014_BFnature12965_MOESM302_ESM.ppt" id="MOESM302" orientation="portrait"><caption><p>PowerPoint slide for Fig. 3</p></caption></media>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="41586_2014_BFnature12965_MOESM303_ESM.ppt" id="MOESM303" orientation="portrait"><caption><p>PowerPoint slide for Fig. 4</p></caption></media>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="41586_2014_BFnature12965_MOESM304_ESM.ppt" id="MOESM304" orientation="portrait"><caption><p>PowerPoint slide for Fig. 5</p></caption></media>
</p>
          </sec>
        </app>
      </app-group>
      <fn-group>
        <fn>
          <p>The primary and processed data used to generate the analyses presented here can be downloaded by registered users from The Cancer Genome Atlas at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp">https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp</ext-link>. All of the primary sequence files are deposited in CGHub and all other data are deposited at the Data Coordinating Center (DCC) for public access (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cghub.ucsc.edu/">https://cghub.ucsc.edu/</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/docs/publications/blca_2013/">https://tcga-data.nci.nih.gov/docs/publications/blca_2013/</ext-link>).</p>
        </fn>
        <fn>
          <p>
            <bold>Change history</bold>
          </p>
          <p>3/19/2014</p>
          <p>Sequences in figure 2a were incorrect and have been fixed.</p>
        </fn>
      </fn-group>
      <ack>
        <title>Acknowledgements</title>
        <p>We are grateful to all of the patients and families who contributed to this study, as well as C. Gunter and L. Chastain for scientific editing and M. Sheth, J. Zhang and C. Ron Bouchard for administrative support. This work was supported by the following grants from the United States National Institutes of Health: U54 HG003273, U54 HG003067, U54 HG003079, U24 CA143799, U24 CA143835, U24 CA143840, U24 CA143843, U24 CA143845, U24 CA143848, U24 CA143858, U24 CA143866, U24 CA143867, U24 CA143882, U24 CA143883, U24 CA144025 and P01 CA120964. Additional personnel and funding sources are acknowledged in the <xref rid="MOESM305" ref-type="media">Supplementary Information</xref>.</p>
      </ack>
      <notes notes-type="author-contribution">
        <title>Author Contributions</title>
        <p>The Cancer Genome Atlas research network contributed collectively to this study. Biospecimens were provided by the tissue source sites and processed by the Biospecimen Core Resource. Data generation and analyses were performed by the genome-sequencing centres, cancer genome-characterization centres and genome data analysis centres. All data were released through the Data Coordinating Center. Project activities were coordinated by the NCI and NHGRI project teams. We also acknowledge the following TCGA investigators of the Bladder Analysis Working Group who contributed substantially to the project. Project leaders: J. N. Weinstein and S. P. Lerner. Data coordinator: C. J. Creighton. Analysis coordinators: R. Akbani and J. Kim. Manuscript coordinator: M. B. Morgan. Project coordinator: M. Sheth. Writing team: J. N. Weinstein, D. J. Kwiatkowski, S. P. Lerner, C. J. Creighton, P. W. Laird, R. Kucherlapati, R. Akbani, X. Su, K. A. Hoadley and M. C. Ryan. Clinical expertise: S. Lerner, D. J. Kwiatkowski, J. E. Rosenberg and D. Bajorin. Pathology review: H. Al-Ahmadie, B. A. Czerniak, D. Hansel, V. Reuter and B. Robinson. DNA sequence and copy number analysis: J. Kim, D. J. Kwiatkowski, A. D. Cherniack and J. E. Rosenberg. DNA methylation analysis: P. W. Laird and T. Hinoue. mRNA analysis: K. A. Hoadley, W. Y. Kim, J. S. Damrauer, W. Zhang, Y. Liu and R. Akbani. miRNA analysis: G. Robertson and A. J. Mungall. Transcript splicing analysis: M. Ryan and J. N. Weinstein. Protein analysis: R. Akbani and G. B. Mills. APOBEC: D. A. Gordenin. Pathway/integrated analysis: C. J. Creighton, N. Schultz, Evan O. Paull and J. Stuart. Chromosomal rearrangements and viral integration: X. Su, R. Kucherlapati, N. Santoso, S. Lee and M. Parfenov. Batch effects: R. Akbani and J. N. Weinstein. Manuscript review: R. Gibbs, C. Gunter and M. Meyerson. Contact PIs: J. N. Weinstein, S. P. Lerner and D. J. Kwiatkowski.</p>
      </notes>
      <notes notes-type="COI-statement">
        <title>Competing interests</title>
        <p>The author declare no competing financial interests.</p>
      </notes>
      <ref-list id="Bib1">
        <title>References</title>
        <ref id="CR1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Global cancer statistics</article-title>
            <source>CA Cancer J. Clin.</source>
            <year>2011</year>
            <volume>61</volume>
            <fpage>69</fpage>
            <lpage>90</lpage>
            <pub-id pub-id-type="doi">10.3322/caac.20107</pub-id>
            <pub-id pub-id-type="pmid">21296855</pub-id>
          </element-citation>
        </ref>
        <ref id="CR2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Forbes</surname>
                <given-names>SA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer</article-title>
            <source>Nucleic Acids Res.</source>
            <year>2011</year>
            <volume>39</volume>
            <fpage>D945</fpage>
            <lpage>D950</lpage>
            <pub-id pub-id-type="doi">10.1093/nar/gkq929</pub-id>
            <pub-id pub-id-type="pmid">20952405</pub-id>
            <pub-id pub-id-type="pmcid">PMC3013785</pub-id>
          </element-citation>
        </ref>
        <ref id="CR3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Goebell</surname>
                <given-names>PJ</given-names>
              </name>
              <name name-style="western">
                <surname>Knowles</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium</article-title>
            <source>Urol. Oncol.</source>
            <year>2010</year>
            <volume>28</volume>
            <fpage>409</fpage>
            <lpage>428</lpage>
            <pub-id pub-id-type="doi">10.1016/j.urolonc.2010.04.003</pub-id>
            <pub-id pub-id-type="pmid">20610279</pub-id>
          </element-citation>
        </ref>
        <ref id="CR4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gui</surname>
                <given-names>Y</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder</article-title>
            <source>Nature Genet.</source>
            <year>2011</year>
            <volume>43</volume>
            <fpage>875</fpage>
            <lpage>878</lpage>
            <pub-id pub-id-type="doi">10.1038/ng.907</pub-id>
            <pub-id pub-id-type="pmid">21822268</pub-id>
            <pub-id pub-id-type="pmcid">PMC5373841</pub-id>
          </element-citation>
        </ref>
        <ref id="CR5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hurst</surname>
                <given-names>CD</given-names>
              </name>
              <name name-style="western">
                <surname>Platt</surname>
                <given-names>FM</given-names>
              </name>
              <name name-style="western">
                <surname>Taylor</surname>
                <given-names>CF</given-names>
              </name>
              <name name-style="western">
                <surname>Knowles</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis</article-title>
            <source>Clin. Cancer Res.</source>
            <year>2012</year>
            <volume>18</volume>
            <fpage>5865</fpage>
            <lpage>5877</lpage>
            <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1807</pub-id>
            <pub-id pub-id-type="pmid">22932667</pub-id>
            <pub-id pub-id-type="pmcid">PMC5081094</pub-id>
          </element-citation>
        </ref>
        <ref id="CR6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lindgren</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma</article-title>
            <source>PLoS ONE</source>
            <year>2012</year>
            <volume>7</volume>
            <fpage>e38863</fpage>
            <pub-id pub-id-type="doi">10.1371/journal.pone.0038863</pub-id>
            <pub-id pub-id-type="pmid">22685613</pub-id>
            <pub-id pub-id-type="pmcid">PMC3369837</pub-id>
          </element-citation>
        </ref>
        <ref id="CR7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Williams</surname>
                <given-names>SV</given-names>
              </name>
              <name name-style="western">
                <surname>Hurst</surname>
                <given-names>CD</given-names>
              </name>
              <name name-style="western">
                <surname>Knowles</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Oncogenic FGFR3 gene fusions in bladder cancer</article-title>
            <source>Hum. Mol. Genet.</source>
            <year>2013</year>
            <volume>22</volume>
            <fpage>795</fpage>
            <lpage>803</lpage>
            <pub-id pub-id-type="doi">10.1093/hmg/dds486</pub-id>
            <pub-id pub-id-type="pmid">23175443</pub-id>
            <pub-id pub-id-type="pmcid">PMC3554204</pub-id>
          </element-citation>
        </ref>
        <ref id="CR8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wu</surname>
                <given-names>YM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Identification of targetable FGFR gene fusions in diverse cancers</article-title>
            <source>Cancer Discov.</source>
            <year>2013</year>
            <volume>3</volume>
            <fpage>636</fpage>
            <lpage>647</lpage>
            <pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0050</pub-id>
            <pub-id pub-id-type="pmid">23558953</pub-id>
            <pub-id pub-id-type="pmcid">PMC3694764</pub-id>
          </element-citation>
        </ref>
        <ref id="CR9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lawrence</surname>
                <given-names>MS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutational heterogeneity in cancer and the search for new cancer-associated genes</article-title>
            <source>Nature</source>
            <year>2013</year>
            <volume>499</volume>
            <fpage>214</fpage>
            <lpage>218</lpage>
            <pub-id pub-id-type="doi">10.1038/nature12213</pub-id>
            <pub-id pub-id-type="pmid">23770567</pub-id>
            <pub-id pub-id-type="pmcid">PMC3919509</pub-id>
          </element-citation>
        </ref>
        <ref id="CR10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cibulskis</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title>
            <source>Nature Biotechnol.</source>
            <year>2013</year>
            <volume>31</volume>
            <fpage>213</fpage>
            <lpage>219</lpage>
            <pub-id pub-id-type="doi">10.1038/nbt.2514</pub-id>
            <pub-id pub-id-type="pmid">23396013</pub-id>
            <pub-id pub-id-type="pmcid">PMC3833702</pub-id>
          </element-citation>
        </ref>
        <ref id="CR11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lawrence</surname>
                <given-names>MS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Discovery and saturation analysis of cancer genes across 21 tumour types</article-title>
            <source>Nature</source>
            <year>2014</year>
            <volume>505</volume>
            <fpage>495</fpage>
            <lpage>501</lpage>
            <pub-id pub-id-type="doi">10.1038/nature12912</pub-id>
            <pub-id pub-id-type="pmid">24390350</pub-id>
            <pub-id pub-id-type="pmcid">PMC4048962</pub-id>
          </element-citation>
        </ref>
        <ref id="CR12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Warfel</surname>
                <given-names>NA</given-names>
              </name>
              <name name-style="western">
                <surname>El-Deiry</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>p21<sup>WAF1</sup> and tumourigenesis: 20 years after</article-title>
            <source>Curr. Opin. Oncol.</source>
            <year>2013</year>
            <volume>25</volume>
            <fpage>52</fpage>
            <lpage>58</lpage>
            <pub-id pub-id-type="doi">10.1097/CCO.0b013e32835b639e</pub-id>
            <pub-id pub-id-type="pmid">23159848</pub-id>
          </element-citation>
        </ref>
        <ref id="CR13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lehmann</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases</article-title>
            <source>Genes Dev.</source>
            <year>2001</year>
            <volume>15</volume>
            <fpage>15</fpage>
            <lpage>23</lpage>
            <pub-id pub-id-type="doi">10.1101/gad.859501</pub-id>
            <pub-id pub-id-type="pmid">11156600</pub-id>
          </element-citation>
        </ref>
        <ref id="CR14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tontonoz</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARγ and RXRα</article-title>
            <source>Nucleic Acids Res.</source>
            <year>1994</year>
            <volume>22</volume>
            <fpage>5628</fpage>
            <lpage>5634</lpage>
            <pub-id pub-id-type="doi">10.1093/nar/22.25.5628</pub-id>
            <pub-id pub-id-type="pmid">7838715</pub-id>
            <pub-id pub-id-type="pmcid">PMC310126</pub-id>
          </element-citation>
        </ref>
        <ref id="CR15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shibata</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy</article-title>
            <source>Proc. Natl Acad. Sci. USA</source>
            <year>2008</year>
            <volume>105</volume>
            <fpage>13568</fpage>
            <lpage>13573</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.0806268105</pub-id>
            <pub-id pub-id-type="pmid">18757741</pub-id>
            <pub-id pub-id-type="pmcid">PMC2533230</pub-id>
          </element-citation>
        </ref>
        <ref id="CR16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Yu</surname>
                <given-names>Q</given-names>
              </name>
              <name name-style="western">
                <surname>Chng</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>TXNIP (VDUP-1, TBP-2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms</article-title>
            <source>Int. J. Biochem. Cell Biol.</source>
            <year>2011</year>
            <volume>43</volume>
            <fpage>1668</fpage>
            <lpage>1673</lpage>
            <pub-id pub-id-type="doi">10.1016/j.biocel.2011.09.005</pub-id>
            <pub-id pub-id-type="pmid">21964212</pub-id>
          </element-citation>
        </ref>
        <ref id="CR17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Solomon</surname>
                <given-names>DA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutational inactivation of STAG2 causes aneuploidy in human cancer</article-title>
            <source>Science</source>
            <year>2011</year>
            <volume>333</volume>
            <fpage>1039</fpage>
            <lpage>1043</lpage>
            <pub-id pub-id-type="doi">10.1126/science.1203619</pub-id>
            <pub-id pub-id-type="pmid">21852505</pub-id>
            <pub-id pub-id-type="pmcid">PMC3374335</pub-id>
          </element-citation>
        </ref>
        <ref id="CR18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Samowitz</surname>
                <given-names>WS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer</article-title>
            <source>J. Natl. Cancer Inst.</source>
            <year>2006</year>
            <volume>98</volume>
            <fpage>1731</fpage>
            <lpage>1738</lpage>
            <pub-id pub-id-type="doi">10.1093/jnci/djj468</pub-id>
            <pub-id pub-id-type="pmid">17148775</pub-id>
          </element-citation>
        </ref>
        <ref id="CR19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Nik-Zainal</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutational processes molding the genomes of 21 breast cancers</article-title>
            <source>Cell</source>
            <year>2012</year>
            <volume>149</volume>
            <fpage>979</fpage>
            <lpage>993</lpage>
            <pub-id pub-id-type="doi">10.1016/j.cell.2012.04.024</pub-id>
            <pub-id pub-id-type="pmid">22608084</pub-id>
            <pub-id pub-id-type="pmcid">PMC3414841</pub-id>
          </element-citation>
        </ref>
        <ref id="CR20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Roberts</surname>
                <given-names>SA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions</article-title>
            <source>Mol. Cell</source>
            <year>2012</year>
            <volume>46</volume>
            <fpage>424</fpage>
            <lpage>435</lpage>
            <pub-id pub-id-type="doi">10.1016/j.molcel.2012.03.030</pub-id>
            <pub-id pub-id-type="pmid">22607975</pub-id>
            <pub-id pub-id-type="pmcid">PMC3361558</pub-id>
          </element-citation>
        </ref>
        <ref id="CR21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Transforming fusions of FGFR and TACC genes in human glioblastoma</article-title>
            <source>Science</source>
            <year>2012</year>
            <volume>337</volume>
            <fpage>1231</fpage>
            <lpage>1235</lpage>
            <pub-id pub-id-type="doi">10.1126/science.1220834</pub-id>
            <pub-id pub-id-type="pmid">22837387</pub-id>
            <pub-id pub-id-type="pmcid">PMC3677224</pub-id>
          </element-citation>
        </ref>
        <ref id="CR22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Oneyama</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways</article-title>
            <source>Oncogene</source>
            <year>2011</year>
            <volume>30</volume>
            <fpage>3489</fpage>
            <lpage>3501</lpage>
            <pub-id pub-id-type="doi">10.1038/onc.2011.63</pub-id>
            <pub-id pub-id-type="pmid">21383697</pub-id>
          </element-citation>
        </ref>
        <ref id="CR23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Yoshino</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Aberrant expression of microRNAs in bladder cancer</article-title>
            <source>Nature Rev. Urol.</source>
            <year>2013</year>
            <volume>10</volume>
            <fpage>396</fpage>
            <lpage>404</lpage>
            <pub-id pub-id-type="doi">10.1038/nrurol.2013.113</pub-id>
            <pub-id pub-id-type="pmid">23712207</pub-id>
          </element-citation>
        </ref>
        <ref id="CR24">
          <label>24</label>
          <mixed-citation publication-type="other">Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. <italic toggle="yes">Nature</italic><bold>490</bold>, 61–70 (2012)<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11412</pub-id><pub-id pub-id-type="pmcid">PMC3465532</pub-id><pub-id pub-id-type="pmid">23000897</pub-id></mixed-citation>
        </ref>
        <ref id="CR25">
          <label>25</label>
          <mixed-citation publication-type="other">Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. <italic toggle="yes">Nature</italic><bold>489</bold>, 519–525 (2012)<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11404</pub-id><pub-id pub-id-type="pmcid">PMC3466113</pub-id><pub-id pub-id-type="pmid">22960745</pub-id></mixed-citation>
        </ref>
        <ref id="CR26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ho</surname>
                <given-names>PL</given-names>
              </name>
              <name name-style="western">
                <surname>Kurtova</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Chan</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Normal and neoplastic urothelial stem cells: getting to the root of the problem</article-title>
            <source>Nature Rev. Urol.</source>
            <year>2012</year>
            <volume>9</volume>
            <fpage>583</fpage>
            <lpage>594</lpage>
            <pub-id pub-id-type="doi">10.1038/nrurol.2012.142</pub-id>
            <pub-id pub-id-type="pmid">22890301</pub-id>
            <pub-id pub-id-type="pmcid">PMC3468664</pub-id>
          </element-citation>
        </ref>
        <ref id="CR27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Sjodahl</surname>
                <given-names>G</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A molecular taxonomy for urothelial carcinoma</article-title>
            <source>Clin. Cancer Res.</source>
            <year>2012</year>
            <volume>18</volume>
            <fpage>3377</fpage>
            <lpage>3386</lpage>
            <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-0077-T</pub-id>
            <pub-id pub-id-type="pmid">22553347</pub-id>
          </element-citation>
        </ref>
        <ref id="CR28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Korpal</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Lee</surname>
                <given-names>ES</given-names>
              </name>
              <name name-style="western">
                <surname>Hu</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Kang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2</article-title>
            <source>J. Biol. Chem.</source>
            <year>2008</year>
            <volume>283</volume>
            <fpage>14910</fpage>
            <lpage>14914</lpage>
            <pub-id pub-id-type="doi">10.1074/jbc.C800074200</pub-id>
            <pub-id pub-id-type="pmid">18411277</pub-id>
            <pub-id pub-id-type="pmcid">PMC3258899</pub-id>
          </element-citation>
        </ref>
        <ref id="CR29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ryan</surname>
                <given-names>MC</given-names>
              </name>
              <name name-style="western">
                <surname>Cleland</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Kim</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Wong</surname>
                <given-names>WC</given-names>
              </name>
              <name name-style="western">
                <surname>Weinstein</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts</article-title>
            <source>Bioinformatics</source>
            <year>2012</year>
            <volume>28</volume>
            <fpage>2385</fpage>
            <lpage>2387</lpage>
            <pub-id pub-id-type="doi">10.1093/bioinformatics/bts452</pub-id>
            <pub-id pub-id-type="pmid">22820202</pub-id>
            <pub-id pub-id-type="pmcid">PMC3436850</pub-id>
          </element-citation>
        </ref>
        <ref id="CR30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Christofk</surname>
                <given-names>HR</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth</article-title>
            <source>Nature</source>
            <year>2008</year>
            <volume>452</volume>
            <fpage>230</fpage>
            <lpage>233</lpage>
            <pub-id pub-id-type="doi">10.1038/nature06734</pub-id>
            <pub-id pub-id-type="pmid">18337823</pub-id>
          </element-citation>
        </ref>
        <ref id="CR31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Vaske</surname>
                <given-names>CJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM</article-title>
            <source>Bioinformatics</source>
            <year>2010</year>
            <volume>26</volume>
            <fpage>i237</fpage>
            <lpage>i245</lpage>
            <pub-id pub-id-type="doi">10.1093/bioinformatics/btq182</pub-id>
            <pub-id pub-id-type="pmid">20529912</pub-id>
            <pub-id pub-id-type="pmcid">PMC2881367</pub-id>
          </element-citation>
        </ref>
        <ref id="CR32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cancer Genome Atlas Research Network</surname>
              </name>
            </person-group>
            <article-title>Comprehensive molecular characterization of clear cell renal cell carcinoma</article-title>
            <source>Nature</source>
            <year>2013</year>
            <volume>499</volume>
            <fpage>43</fpage>
            <lpage>49</lpage>
            <pub-id pub-id-type="doi">10.1038/nature12222</pub-id>
            <pub-id pub-id-type="pmid">23792563</pub-id>
            <pub-id pub-id-type="pmcid">PMC3771322</pub-id>
          </element-citation>
        </ref>
        <ref id="CR33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bose</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Activating HER2 mutations in HER2 gene amplification negative breast cancer</article-title>
            <source>Cancer Discov.</source>
            <year>2013</year>
            <volume>3</volume>
            <fpage>224</fpage>
            <lpage>237</lpage>
            <pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0349</pub-id>
            <pub-id pub-id-type="pmid">23220880</pub-id>
            <pub-id pub-id-type="pmcid">PMC3570596</pub-id>
          </element-citation>
        </ref>
        <ref id="CR34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Greulich</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2</article-title>
            <source>Proc. Natl Acad. Sci. USA</source>
            <year>2012</year>
            <volume>109</volume>
            <fpage>14476</fpage>
            <lpage>14481</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.1203201109</pub-id>
            <pub-id pub-id-type="pmid">22908275</pub-id>
            <pub-id pub-id-type="pmcid">PMC3437859</pub-id>
          </element-citation>
        </ref>
        <ref id="CR35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jaiswal</surname>
                <given-names>BS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Oncogenic ERBB3 mutations in human cancers</article-title>
            <source>Cancer Cell</source>
            <year>2013</year>
            <volume>23</volume>
            <fpage>603</fpage>
            <lpage>617</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ccr.2013.04.012</pub-id>
            <pub-id pub-id-type="pmid">23680147</pub-id>
          </element-citation>
        </ref>
        <ref id="CR36">
          <label>36</label>
          <mixed-citation publication-type="other">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer. Vol. <bold>1.2012</bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp%23site">http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site</ext-link> (2012)</mixed-citation>
        </ref>
        <ref id="CR37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>von der Maase</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer</article-title>
            <source>J. Clin. Oncol.</source>
            <year>2005</year>
            <volume>23</volume>
            <fpage>4602</fpage>
            <lpage>4608</lpage>
            <pub-id pub-id-type="doi">10.1200/JCO.2005.07.757</pub-id>
            <pub-id pub-id-type="pmid">16034041</pub-id>
          </element-citation>
        </ref>
        <ref id="CR38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Iyer</surname>
                <given-names>G</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genome sequencing identifies a basis for everolimus sensitivity</article-title>
            <source>Science</source>
            <year>2012</year>
            <volume>338</volume>
            <fpage>221</fpage>
            <pub-id pub-id-type="doi">10.1126/science.1226344</pub-id>
            <pub-id pub-id-type="pmid">22923433</pub-id>
            <pub-id pub-id-type="pmcid">PMC3633467</pub-id>
          </element-citation>
        </ref>
        <ref id="CR39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Filippakopoulos</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Selective inhibition of BET bromodomains</article-title>
            <source>Nature</source>
            <year>2010</year>
            <volume>468</volume>
            <fpage>1067</fpage>
            <lpage>1073</lpage>
            <pub-id pub-id-type="doi">10.1038/nature09504</pub-id>
            <pub-id pub-id-type="pmid">20871596</pub-id>
            <pub-id pub-id-type="pmcid">PMC3010259</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </article>
</pmc-articleset>
